Materials and methods for modulating an immune response
Patent Information
- Application Number
- EP2021760487
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-11
- Filing Date
- 2021-02-26
- Publication Date
- 2024-11-13
AI Technical Summary
Current T Cell Receptor (TCR) redirection technologies are inadequate in effectively targeting and modulating the immune response against cancer cells, particularly in redirecting T cells to specific antigens on cancer cells for targeted therapy.
Development of TRGV9 antibodies, including multispecific antibodies that bind to TRGV9 and additional targets like CD123, CD33, TRBC1, BCMA, and PSMA, to recruit T cells to cancer cells, inducing cytotoxicity and modulating the immune response.
The TRGV9 antibodies effectively recruit T cells to cancer cells, inducing targeted cytotoxicity and modulating the immune response, potentially leading to improved cancer treatment outcomes by enhancing T cell-dependent cytotoxicity against cancer cells.
Smart Images

Figure 1.1
Abstract
Description
MATERIALS AND METHODS FOR MODULATING AN IMMUNERESPONSECROSS-REFERENCE TO RELATED APPLICATIONSThis application claims the benefit of U.S. Serial No. 62 / 982,492 filed February 27, 2020; U.S. Serial No. 62 / 982,505 filed February 27, 2020; U.S. Serial No. 62 / 982,374 filed February 27, 2020; U.S. Serial No. 62 / 982,462 filed February 27, 2020; U.S. Serial No. 62 / 982,478 filed February 27, 2020; U.S. Serial No. 62 / 982,469 filed February 27, 2020; U.S. Serial No. 62 / 982,525 filed February 27, 2020; U.S. Serial No. 62 / 982,535 filed February 27, 2020; U.S. Serial No. 62 / 982,574 filed February 27, 2020; U.S. Serial No. 62 / 982,591 filed February 27, 2020; U.S. Serial No. 62 / 982,664 filed February 27, 2020; U.S. Serial No. 62 / 982,669 filed February 27, 2020; U.S. Serial No. 62 / 982,602 filed February 27, 2020; U.S. Serial No. 62 / 982,548 filed February 27, 2020; U.S. Serial No. 62 / 988,996 filed March 13, 2020; U.S. Serial No. 62 / 989,002 filed March 13, 2020; U.S. Serial No. 62 / 989,006 filed March 13, 2020; U.S. Serial No. 62 / 989,010 filed March 13, 2020; U.S. Serial No. 62 / 989,018 filed March 13, 2020; U.S. Serial No. 62 / 989,024 filed March 13, 2020; U.S. Serial No. 62 / 989,027 filed March 13, 2020; U.S. Serial No. 62 / 989,036 filed March 13, 2020; U.S. Serial No. 62 / 989,042 filed March 13, 2020; U.S. Serial No. 62 / 989,045 filed March 13, 2020; U.S. Serial No. 62 / 989,052 filed March 13, 2020; U.S. Serial No. 62 / 989,057 filed March 13, 2020; U.S. Serial No. 62 / 989,068 filed March 13, 2020; U.S. Serial No. 62 / 989,075 filed March 13, 2020; International Serial No. PCT / US20 / 31749 filed May 7, 2020; U.S. Serial No. 63 / 074,655 filed September 4, 2020; U.S. Serial No. 63 / 074,676 filed September 4, 2020; U.S. Serial No.63 / 074,854 filed September 4, 2020; U.S. Serial No. 63 / 074,700 filed September 4, 2020; U.S. Serial No. 63 / 074,749 filed September 4, 2020; U.S. Serial No.63 / 074,735 filed September 4, 2020; U.S. Serial No. 63 / 074,839 filed September 4, 2020; U.S. Serial No. 63 / 074,759 filed September 4, 2020; U.S. Serial No.63 / 074,903 filed September 4, 2020; U.S. Serial No. 63 / 074,893 filed September 4, 2020; U.S. Serial No. 63 / 074,925 filed September 4, 2020; U.S. Serial No.63 / 074,937 filed September 4, 2020; U.S. Serial No. 63 / 074,962 filed September 4, 2020; U.S. Serial No. 63 / 074,946 filed September 4, 2020; U.S. Serial No.63 / 112,462 filed November 11, 2020; and U.S. Serial No. 63 / 112,475 filed November11, 2020.FIELD
[0001] This invention relates to, among other things, T Cell Receptor (TCR) redirection technologies, such as those targeting T cell Receptor Gamma Variable 9 (TRGV9) molecules, including TRGV9 antibodies, bispecific antibodies, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies, and methods of using the antibodies to modulate an immune response to cancer cells, are also provided.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file “ 14620-381-228_SEQLISTING” and a creation date of February 22, 2021 and having a size of 440,714 bytes. The sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.SUMMARY
[0003] Provided are T Cell Receptor redirection technologies, including, for example, TRGV9 molecules, such as TRGV9 antibodies and multispecific antibodies, as well as nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and compositions comprising the antibodies.
[0004] In one aspect, provided herein is an antibody that binds to TRGV9. In some embodiments, the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL).
[0005] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of L7A5 2 (TRGV9 2). In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:34; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8.
[0006] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of L7A5 3 (TRGV9 3). In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 havingan amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:35; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8.
[0007] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of L7A5 4 (TRGV9 4). In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:36; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8.
[0008] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of TRGV9Ab_varl7. In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:66.
[0009] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of TRGV9Ab_var29. In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:67; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:68.
[0010] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of VG9B420. In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 104; and (ii) a VL comprising a VLCDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 105.
[0011] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of VG9SB10SC1087 P18 D08. In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 113; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 114.
[0012] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of VG9SB10SC1087 P18 C12. In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 123; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 124.
[0013] In one embodiment, the TRGV9 antibody has a VH and VL amino acid sequence of VG9SB10SC1087 P19 C03. In one embodiment, the TRGV9 antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 133; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 134.
[0014] In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Rabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VLCDR3 amino acid sequences of the TRGV9 antibody are according to the AbMnumbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3,VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Exemplary numbering system.
[0015] In some embodiments, the antibody binds a TRGV9 antigen. In some embodiments, antibody binds a TRGV9 epitope. In some embodiments, the antibody specifically binds to TRGV9. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form a binding site for an antigen of the TRGV9. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form a binding site for an epitope of the TRGV9. In some embodiments, the TRGV9 is present on the surface of a T cell. In some embodiments, the T cell is a gd T cell.
[0016] In some embodiments, the TRGV9 antibody is chimeric. In some embodiments, the TRGV9 antibody is human. In some embodiments, the TRGV9 antibody is humanized. In certain embodiments, the TRGV9 antibody is an isolated TRGV9 antibody. In some embodiments, the TRGV9 antibody is a TRGV9 antigen binding fragment. In some embodiments, the TRGV9 antigen binding fragment is chimeric. In some embodiments, the TRGV9 antigen binding fragment is human. In some embodiments, a TRGV9 antigen binding fragment is humanized. In certain embodiments, a TRGV9 antigen binding fragment is an isolated TRGV9 antigen binding fragment. In some embodiments, the TRGV9 antibody is an IgG antibody.In some embodiments, the TRGV9 antibody is an IgGl antibody. In some embodiments, the TRGV9 antibody is an IgG2 antibody. In some embodiments, the TRGV9 antibody is an IgG3 antibody. In some embodiments, the TRGV9 antibody is an IgG4 antibody. In some embodiments, the TRGV9 antibody comprises a kappa light chain. In some embodiments, the TRGV9 antibody comprises a lambda light chain. In some embodiments, the TRGV9 antibody is a monoclonal antibody. In some embodiments, the TRGV9 antibody is multivalent. In some embodiments, the TRGV9 antibody is capable of binding at least three antigens. In some embodiments,the TRGV9 antibody is capable of binding at least four antigens. In some embodiments, the TRGV9 antibody is capable of binding at least five antigens. In some embodiments, the TRGV9 antibody is a multispecific antibody. In some embodiments, the TRGV9 antibody is a bispecific antibody. In some embodiments, the TRGV9 antibody is a trispecific antibody. In some embodiments, the TRGV9 antibody is a quadraspecific antibody.
[0017] In one specific embodiment, the TRGV9 antibody is a multispecific TRGV9 antibody. In one specific embodiment, the multispecific TRGV9 antibody is a bispecific TRGV9 antibody.
[0018] Thus, in one aspect, provided is a multispecific TRGV9 antibody, comprising a TRGV9 antibody provided herein. In one embodiment, the multispecific TRGV9 antibody comprises: (a) a first binding domain that binds to TRGV9, and (b) a second binding domain that binds to a second target that is not TRGV9.
[0019] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 1 (TRGV9 1). In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:7; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8.
[0020] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 2 (TRGV9 2). In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:34; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8.
[0021] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 3 (TRGV9 3). In oneembodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:35; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8.
[0022] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 4 (TRGV9 4). In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:36; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8.
[0023] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of TRGV9Ab_varl7. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:66.
[0024] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of TRGV9Ab_var29. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:67; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:68.
[0025] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9 B3 RN. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:95; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:96.
[0026] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9B420. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 104; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 105.
[0027] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9SB10SC1087 P18 D08. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 113; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 114.
[0028] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9SB10SC1087 P18 C12. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 123; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 124.
[0029] In one embodiment, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9SB10SC1087 P19 C03. In one embodiment, the first binding domain that binds to TRGV9 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 133; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 134.
[0030] In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Rabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3,VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Exemplary numbering system.
[0031] In some embodiments, the first binding domain binds a TRGV9 antigen.In some embodiments, the first binding domain binds a TRGV9 epitope. In some embodiments, the first binding domain specifically binds to TRGV9. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the first binding domain form a binding site for an antigen of the TRGV9. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the first binding domain form a binding site for an epitope of the TRGV9. In some embodiments, the TRGV9 is present on the surface of a T cell.
[0032] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is not a TRGV9 antigen. In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is not a TRGV9 epitope.
[0033] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is CD123. In one embodiment, the second binding domain that binds to CD123 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 15; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 16.
[0034] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is CD33. In one embodiment, the second target is the C2 domain of CD33. the second target is the V domain of CD33. In one embodiment, the second binding domain that binds to CD33 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:43; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:44.
[0035] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is TRBC1. In one embodiment, the second binding domain that binds to TRBC1 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 55; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:56.
[0036] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is B cell maturation antigen (BCMA). In one embodiment, the second binding domain binds to BCMA. In one embodiment, the second binding domain that binds to BCMA comprises: (i) a VH comprising a VH CDR1, a VHCDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VHCDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 143; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 144.
[0037] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is prostate-specific membrane antigen (PSMA). In one embodiment, the second binding domain binds to PSMA. In one embodiment, the second binding domain that binds to PSMA comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:775; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:776.
[0038] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is expressed by target cell. In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is on the surface of a target cell. In a specific embodiment, the target cell is an undesired cell.
[0039] In one embodiment, the target cell is a cancer cell. In one embodiment, the target cell is a T cell. In one embodiment, the target cell is a B cell. In one embodiment, the target cell is a dendritic cell. In one embodiment, the target cell is a NR cell. In one embodiment, the target cell is a stem cell. In one embodiment, the target cell is a stem cell precursor. In one embodiment, the target cell is a monocyte. In one embodiment, the target cell is a macrophage. In one embodiment, the target cell is a granulocyte. In one embodiment, the target cell is a platelet. In one embodiment, the target cell is an erythrocyte. In one embodiment, the target cell is an endothelial cell. In one embodiment, the target cell is an epithelial cell. In one embodiment, the second target is a pathogen. In one embodiment, the target cell is a cell comprising a pathogen. In one embodiment, the target cell is a blood cell. In one embodiment, the target cell is a myeloid cell.
[0040] In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding domain that binds the second target are according to the Rabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VLCDR3 amino acid sequences of the second binding domain that binds the secondtarget are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding domain that binds the second target are according to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding domain that binds the second target are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1,VL CDR2, and VL CDR3 amino acid sequences of the second binding domain that binds the second target are according to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding domain that binds the second target are according to the Exemplary numbering system.
[0041] In some embodiments, the second binding domain binds an antigen of the second target. In some embodiments, In some embodiments, the second binding domain binds an epitope of the second target. In some embodiments, the second binding domain specifically binds to the second target. In some embodiments, the second binding domain specifically binds an antigen of the second target. In some embodiments, In some embodiments, the second binding domain specifically binds an epitope of the second target. In some embodiments, the VH CDR1, VH CDR2,VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the second binding domain form a binding site for an antigen of the second target. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the second binding domain form a binding site for an epitope of the second target. In some embodiments, the second target is present on the surface of a target cell. In some embodiments, the target cell expressing the second target is killed when the multispecific TRGV9 antibody binds to TRGV9 on the surface of a T cell and the second target. In a specific embodiment, the T cell is a gd T cell.
[0042] In some embodiments, the first binding domain of the multispecific TRGV9 antibody is multivalent. In some embodiments, the first binding domain of the multispecific TRGV9 antibody is capable of binding at least three antigens. In some embodiments, the first binding domain of the multispecific TRGV9 antibody is capable of binding at least four antigens. In some embodiments, the first binding domain of the multispecific TRGV9 antibody is capable of binding at least fiveantigens. In some embodiments, the second binding domain of the multispecific TRGV9 antibody is multivalent. In some embodiments, the second binding domain of the multispecific TRGV9 antibody is capable of binding at least three antigens. In some embodiments, the second binding domain of the multispecific TRGV9 antibody is capable of binding at least four antigens. In some embodiments, the second binding domain of the multispecific TRGV9 antibody is capable of binding at least five antigens.
[0043] In some embodiments, the first binding domain is humanized. In some embodiments, the second binding domain is humanized. In some embodiments, both the first binding domain and the second binding domain are humanized. In some embodiments, the multispecific TRGV9 antibody comprises a kappa light chain. In some embodiments, the multispecific TRGV9 antibody comprises a lambda light chain. In some embodiments, the multispecific TRGV9 antibody is an IgG antibody. In some embodiments, the IgG antibody is an IgGl antibody. In some embodiments, the IgG antibody is an IgG2 antibody. In some embodiments, the IgG antibody is an IgG3 antibody. In some embodiments, the IgG antibody is an IgG4 antibody.
[0044] In some embodiments, the multispecific TRGV9 antibody induces T cell dependent cytotoxicity of a target cell expressing the second target in vitro with an EC50 of less than about 500 pM. In some embodiments, the multispecific TRGV9 antibody induces T cell dependent cytotoxicity of a target cell expressing the second target in vitro with an EC50 of less than about 300 pM. In some embodiments, the multispecific TRGV9 antibody induces T cell dependent cytotoxicity of a target cell expressing the second target in vitro with an EC50 of less than about 160 pM. In some embodiments, the EC50 is assessed with a mixture of T cell effector cells and target cells expressing the second target. In some embodiments, the effector cell to target cell ratio is about 0.01 to 1 to about 5 to 1. In some embodiments, the effector cell to target cell ratio is about 0.1 to 1 to about 2 to 1. In some embodiments, the effector cell to target cell ratio is about 1 : 1. In a specific embodiment, the T cell is a gd T cell. In one embodiment, target cells are Kasumi-3 AML target cells.
[0045] In another aspect, provided is a nucleic acid encoding a TRGV9 antibody provided herein. Also provided is a vector comprising a nucleic acid encoding a TRGV9 antibody provided herein. Also provided is a host cell comprising a vector comprising a nucleic acid encoding a TRGV9 antibody provided herein. Alsoprovided is a kit comprising vector comprising a nucleic acid encoding a TRGV9 antibody provided herein, and packaging for the same. Also provided are methods of making a TRGV9 antibody provided herein, comprising culturing a cell comprising a nucleic acid encoding TRGV9 antibody under conditions to produce the TRGV9 antibody. In another aspect, provided is a kit comprising a TRGV9 antibody provided herein, and packaging for the same. In another aspect, provided is a pharmaceutical composition comprising a TRGV9 antibody provided herein, and a pharmaceutically acceptable carrier. In another aspect, provided is a method of producing a pharmaceutical composition comprising a TRGV9 antibody provided herein, comprising combining the TRGV9 antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition. In a specific embodiment, the TRGV9 antibody is a multispecific TRGV9 antibody provided herein.
[0001] In another aspect, provided is a multispecific TRGV9 antibody comprising: a first means capable of binding TRGV9; and a second means capable of binding a second target. In certain embodiments, the second target is not TRGV9. In another aspect, provided is a multispecific TRGV9 antibody comprising: a first means that binds to TRGV9; and a second means that binds to a second target. In certain embodiments, the second target is not TRGV9. In some embodiments, the TRGV9 is on the surface of a T cell. In certain embodiments, the T cell is a gd T cell. In some embodiments, the first means is capable of specifically binding the TRGV9. In some embodiments, the first means specifically binds the TRGV9. In one embodiment, the TRGV9 is a TRGV9 antigen. In another embodiment, the TRGV9 is a TRGV9 epitope. In one embodiment, the first means is a paratope. In some embodiments, the paratope is a paratope of a TRGV9 antibody provided herein. In one embodiment, the first means is an antibody. In some embodiments, the antibody is TRGV9 antibody provided herein. In some embodiments, the TRGV9 antibody is an antigen binding fragment. In some embodiments, the second means is capable of specifically binding the second target. In some embodiments, the second means specifically binds the second target. In some embodiments, the second target is an antigen of the second target. In some embodiments, the second target is an epitope of the second target. In some embodiments, the second target is on the surface of a target cell. In some embodiments, the second target is CD 123. In some embodiments,the second target is CD33. In some embodiments, the second target is TRBC1. In some embodiments, the second target is BCMA. In some embodiments, the second target is PSMA. In one embodiment, the second means is a paratope. In some embodiments, the paratope is a paratope of a second binding arm provided herein. In some embodiments, the paratope is a paratope of a CD 123 antibody provided herein. In some embodiments, the paratope is a paratope of a CD33 antibody provided herein. In some embodiments, the paratope is a paratope of a TRBC1 antibody provided herein. In some embodiments, the paratope is a paratope of a BCMA antibody provided herein. In some embodiments, the paratope is a paratope of a PSMA antibody provided herein. In one embodiment, the second means is an antibody that binds a second target provided herein. In some embodiments, the second means is a CD123 antibody provided herein. In one embodiments, the CD123 antibody is an antigen binding fragment thereof. In some embodiments, the second means is a CD33 antibody provided herein. In one embodiments, the CD33 antibody is an antigen binding fragment thereof. In some embodiments, the second means is a TRBC1 antibody provided herein. In one embodiments, the TRBC1 antibody is an antigen binding fragment thereof. In some embodiments, the second means is a BCMA antibody provided herein. In one embodiments, the BCMA antibody is an antigen binding fragment thereof. In some embodiments, the second means is a PSMA antibody provided herein. In one embodiments, the PSMA antibody is an antigen binding fragment thereof.
[0002] In another aspect, provided is a process for making an antibody that binds to more than one target, the process comprising: a step for performing a function of obtaining a first binding domain capable of binding to TRGV9; a step for performing a function of obtaining a second binding domain capable of binding to a second target; and a step for performing a function of providing an antibody capable of binding to TRGV9 and the second target. In some embodiments, the step for performing a function of obtaining a second binding domain capable of binding to second target is repeated n times and further comprises n steps for performing a function of providing a first binding domain capable of binding to TRGV9 and n number of targets, wherein n is at least 2. In certain embodiments, the second target is not TRGV9. In some embodiments, the first binding domain is capable of specifically binding to the TRGV9. In one embodiment, the TRGV9 is a TRGV9 antigen. In another embodiment, the TRGV9 is a TRGV9 epitope. In oneembodiment, the first binding domain binds a TRGV9 antigen. In one embodiment, the first binding domain binds a TRGV9 epitope. In some embodiments, the TRGV9 is on the surface of a T cell. In some embodiments, the T cell is a gd T cell. In some embodiments, the second binding domain is capable of specifically binding to the second target. In one embodiment, the second binding domain binds an antigen of the second target. In one embodiment, the second binding domain binds an epitope of the second target. In some embodiments, the second target is on the surface of a target cell. In some embodiments, the second target is CD 123. In some embodiments, the second target is CD33. In some embodiments, the second target is TRBC1. In some embodiments, the second target is BCMA. In some embodiments, the second target is PSMA. In one embodiment, the target cell is a cancer cell.
[0003] In another aspect, provided is a method of activating a T cell expressing TRGV9, comprising contacting the T cell with a TRGV9 antibody provided herein.In certain embodiments, the contacting results in an increase in CD69, CD25, and / or Granzyme B expression, as compared to a control T cell expressing TRGV9. In another aspect, provided is a method of inactivating a T cell expressing TRGV9, comprising contacting the T cell with an antibody that binds to a TRGV9 provided herein. Also provided is a method of blocking activation a T cell expressing TRGV9, comprising contacting the T cell with an antibody that binds to a TRGV9 provided herein. Also provided is a method of modulating the activity of a T cell expressing TRGV9, comprising contacting the T cell with an antibody that binds to a TRGV9 provided herein. In a specific embodiment, the T cell is a gd T cell. In certain embodiments, the TRGV9 antibody is a multispecific TRGV9 antibody provided herein.
[0004] In another aspect provided is a method of directing a T cell expressing TRGV9 to a target cell, the method comprising contacting the T cell with a multispecific TRGV9 antibody provided herein, wherein the contacting directs the T cell to the target cell. In another aspect provided is a method of inhibiting growth or proliferation of a target cell, the method comprising contacting the target cell with a multispecific TRGV9 antibody provided herein, wherein the contacting inhibits growth or proliferation of the target cell. In some embodiments, the target cell is in the presence of the T cell expressing TRGV9 while in contact with the multispecific TRGV9 antibody. In some embodiments, the target cell expresses a second targetthat is not TRGV9. In some embodiments, the T cell is a gd T cell. In some embodiments, the second target is an antigen of the second target. In some embodiments, the second target is an epitope of the second target. In some embodiments, the second target is on the surface of the target cell. In some embodiments, the second target is CD123. In some embodiments, the second target is CD33. In some embodiments, the second target is TRBC1. In some embodiments, the second target is BCMA. In some embodiments, the second target is PSMA. In one embodiment, the target cell is a cancer cell.
[0005] In another aspect provided is a method for eliminating target cells in a subject, comprising administering an effective amount of a multispecific TRGV9 antibody provided herein to the subject. In another aspect, provided is a method for treating a disease, disorder or condition (hereafter “disease”) caused all or in part by a target cell in a subject, comprising administering an effective amount of a multispecific TRGV9 antibody provided herein to the subject. In another aspect, provided is a method for preventing a disease caused all or in part by a target cell in a subject, comprising administering an effective amount of a multispecific TRGV9 antibody provided herein to the subject. In another aspect, provided is a method for modulating a disease caused all or in part by a target cell in a subject, comprising administering an effective amount of a multispecific TRGV9 antibody provided herein to the subject. In some embodiments, the target cell expresses a second target that is not TRGV9. In some embodiments, the second target is on the surface of the target cell. In some embodiments, the second target is CD123. In some embodiments, the second target is CD33. In some embodiments, the second target is TRBC1. In some embodiments, the second target is BCMA. In some embodiments, the second target is PSMA. In one embodiment, the target cell is a cancer cell. In one embodiment, the target cell is a T cell. In one embodiment, the target cell is a B cell. In one embodiment, the target cell is a dendritic cell. In one embodiment, the target cell is a NK cell. In one embodiment, the target cell is a stem cell. In one embodiment, the target cell is a stem cell precursor. In one embodiment, the target cell is a monocyte. In one embodiment, the target cell is a macrophage. In one embodiment, the target cell is a granulocyte. In one embodiment, the target cell is a platelet. In one embodiment, the target cell is an erythrocyte. In one embodiment, the target cell is an endothelial cell. In one embodiment, the target cell is an epithelialcell. In one embodiment, the second target is a pathogen. In one embodiment, the target cell is a cell comprising a pathogen. In one embodiment, the target cell is a blood cell. In one embodiment, the target cell is a myeloid cell. In some embodiments, the second target is on a cancer cell. In some embodiments, the target cell is a cancer cell. In a specific embodiment, the second target is on the surface of a cancer cell. In certain embodiments, the second target is an antigen on the surface of a cancer cell. In some embodiments, the antigen on the surface of the cancer cell is a tumor-specific antigen, a tumor-associated antigen, or a neoantigen In a specific embodiment, the disease is a cancer. In some embodiments, the subject is a subject in need thereof. In some embodiments, the subject is a human. In certain embodiments, the method further comprises identifying a subject in need thereof.BRIEF DESCRIPTION OF THE DRAWINGS
[0006] The foregoing summary, as well as the following detailed description of specific embodiments of the present application, will be better understood when read in conjunction with the appended drawings. It should be understood, however, that the application is not limited to the precise embodiments shown in the drawings.
[0007] FIG. 1 shows a schematic demonstrating the binding of an exemplary multispecific TRGV9 antibody comprising a first binding domain that binds to TRGV9 and a second binding domain that binds to a second target antigen on a target cell to recruit gd T cells to the target cell and to induce target cell death. The second target antigen can be a tumor associated antigen (TAA), and the target cell can be a tumor cell, wherein the anti-TRGV9 / anti-TAA bispecific antibody can to recruit gd T cells to the cancer cell and to induce cancer cell death.
[0008] FIG. 2 shows a graph demonstrating that Zoledronic acid selectively expands Vγ9Vb2 cells from whole peripheral blood mononuclear cells (PBMCs).
[0009] FIGS. 3A-3E show phenotypic characterization of Vγ9+ gd T cells. FIG. 3A shows a schematic depiction of gates used to describe the differentiation of gd T cells (left). Representative FACS-dot plots show the differentiation profile of Vγ9+gd T cells from fresh PBMCs (left) and PBMCs cultured ex vivo with Zoledronic acid + IL-2 + IL-15 for 14 days (right). Numbers in quadrants mirror the frequency (mean ± SEM) of the respective population among fresh and activated ng9+gd T cells. Represented data is mean (± SEM) of five donors (n=5) from a single experiment. FIG. 3B shows numbers in representative dot plots mirroring thefrequency (mean ± SEM) of ng9+gd T cells positive for respective activation marker either from fresh PBMCs (upper row) or PBMCs cultured with Zoledronic acid + IL- 2 + IL-15 for 14 days (lower row). Represented data is mean (± SEM) of seven donors (n=7) for CD62L, CD69, CD44 expression data from two independent experiments. n=5 donors for NKG2D and 2 donors for CD45RO and CD71 expression data respectively from a single experiment. FIG. 3C shows numbers above gates in dot plots depicting the frequency (mean±SEM) of Vγ9+gd T cells positive for respective inhibitory receptor surface expression either from fresh PBMCs (upper row) or PBMCs cultured with Zoledronic acid + IL-2 + IL-15 for day 14 days (lower row). Data shown here is mean (±SEM) of five donors (n=5) for PD1, CTLA4, TIGIT and LAG3 surface expression and seven donors (n=7) for 2B4 and TIM3 surface expression data from two independent experiments. FIG. 3D shows representative FACS dot plots demonstrating the frequency (mean ± SEM) of Vγ9+gd T cells expressing intracellular Granzyme B (left column) and Perforin (right column) from fresh PBMCs (upper row) and PBMCs cultured ex vivo with Zoledronic acid + IL-2 + IL-15 for 14 days (lower row). Depicted data is mean (± SEM) of four (n=4) and seven (n=7) donors for Granzyme B and Perforin data respectively from two independent experiments. FIG. 3E shows bars representing the mean (± SEM) concentration (pg / mL) of cytokine in the cell culture supernatant on day 0 and day 14 of PBMCs culture with Zoledronic acid + IL-2 + IL-15. Represented data is mean (± SEM) of four wells (n=4) from a single donor.
[0010] FIG. 4 shows a histogram demonstrating that VG1 (an anti-TRGV9 / anti- CD123 bispecific antibody) recruits Vγ9+ T cells as demonstrated by conjugate formation between gd T cells and Kasumi-3 cells.
[0011] FIGS. 5A-5C show graphs demonstrating VG1 (anti-TRGV9 / anti-CD123 bispecific antibody) bispecific mediated gd T cell cytotoxicity against Kasumi-3 cells at different effector to target cell ratios (1 : 1 for FIG. 5A; 5:1 for FIG. 5B; and 10: 1 for FIG. 5C)
[0012] FIGS. 6A-6C show graphs demonstrating CD69 (FIG. 6A), CD25 (FIG. 6B), or Granzyme B (FIG. 6C) expression on Vγ9+ gd T cells, non-Vγ9+ gd T cells, and Pan-T cells (non gd T cells) co-cultured with Kasumi-3 cells and VG1, VG3, or no bispecific antibody.
[0013] FIG. 7 shows a schematic demonstrating the binding of an anti- TRGV9 / anti-CD33 bispecific antibody to recruit gd T-cells to a cancer cell that is CD33+ and to induce cancer cell death.
[0014] FIG. 8 shows an SDS-PAGE (non-reducing) gel demonstrating the integrity of the VG4 bispecific antibody.
[0015] FIG. 9 shows a graph demonstrating the binding of anti-CD33 antibody (clone C33B904) to MOLM-13 tumor cell line as measured by FACS.
[0016] FIG. 10 shows a graph demonstrating the binding of anti-CD33 antibody (clone C33B904) to Kasumi-1 tumor cell line as measured by FACS.
[0017] FIG. 11 shows a graph demonstrating the binding of anti-CD33 antibody (clone C33B904) to OCI-AML-3 tumor cell line as measured by FACS.
[0018] FIG. 12 shows a graph demonstrating that the anti-TRGV9 / anti-CD33 bispecific antibody mediated gd T cell cytotoxicity against CD33 expressing Kasumi- 3 cells at 1 : 1 effector to target cell ratio. The effector cells were enriched gd T cells isolated from PBMCs.
[0019] FIG. 13 shows a graph demonstrating that the anti-TRGV9 / anti-CD33 bispecific antibody mediated gd T cell cytotoxicity against CD33 expressing Kasumi- 3 cells at 5: 1 effector to target cell ratio. The effector cells were enriched gd T cells isolated from PBMCs.
[0020] FIG. 14 shows a graph demonstrating that the anti-TRGV9 / anti-CD33 bispecific antibody mediated gd T cell cytotoxicity against CD33 expressing Kasumi- 3 cells at 1 : 1 effector to target cell ratio. The effector cells were healthy donor derived PBMCs.
[0021] FIG. 15 shows a schematic demonstrating the binding of anti- TRGV9 / anti-TRBCl bispecific antibody to recruit gd T-cells to a cancer cell that is TRBC1+ and to induce cancer cell death.
[0022] FIG. 16 shows selective cell binding of anti-TRBCl (JOVI-1 mIgG2a, TRBIBI) to transfected Jurkat cells. The EC50for binding was ~1 to 2 nM. TRBIBI did not show any significant binding to HPB-ALL cell line that endogenously expresses TRBC2 TCR.
[0023] FIG. 17 shows selective protein binding of anti-TRBCl (JOVI-1 mIgG2a, TRBIBI) to a recombinant TCR comprising of TRBCl constant domain(TRB1W16). TRB1B1 did not show any significant binding to a recombinant TCR with TRBC2 constant domain (TRB2W16).
[0024] FIG. 18 shows phenotyping of Vγ9+ cells used for cytotoxicity studies of JOVI-1 x Vg9 bispecific (TRB1B50) from a healthy donor.
[0025] FIG. 19 shows that the anti-TRGV9 / anti-TRBCl bispecific antibody mediates gd T cell cytotoxicity against TRBCl expressing Jurkat cells in vitro. Cytotoxicity values represented here were subtracted of basal cytotoxicity value observed in the absence of bispecific antibody. EC50values were calculated as described in methods. Representative data shown here are from a single experiment.
[0026] FIG. 20 shows bispecific antibody mediated cytotoxicity. Expanded and enriched Vγ9V62 T cells from various donors were used to induce cytotoxicity to Jurkat cell line (E:T ratio 1:1) in presence of Vγ9xJovi at indicated concentrations. Assay was conducted for 16 hrs. Percent dead target cells for various conditions are given in the figure.
[0027] FIG. 21 shows that the anti-TRGV9 / anti-BCMA bispecific antibody (BCV9B106 (B3)) binds gd T cells (left panel) and mediates gd T cell cytotoxicity against BCMA expressing H929 cells in vitro (right panel). EC50values were calculated as described in methods. Representative data shown here are from a single experiment.
[0028] FIG. 22 shows that the anti-TRGV9 / anti-BCMA bispecific antibody (HC1: VG9B420-LH-scFv; HC2: BCMA-Fab (BCMB519-Fab) (BCV9B71.001)) binds gd T cells (left panel) and mediates gd T cell cytotoxicity against BCMA expressing H929 cells in vitro (right panel). EC50values were calculated as described in methods. Representative data shown here are from a single experiment.
[0029] FIG. 23 shows that the anti-TRGV9 / anti-BCMA bispecific antibody (VG9SB10SC1087_P18_D08-Fab RF, BCMA-scFv (BCMB519-scFv ) (BCV9B100.001)) binds gd T cells (left panel) and mediates gd T cell cytotoxicity against BCMA expressing H929 cells in vitro (right panel). EC50values were calculated as described in methods. Representative data shown here are from a single experiment.
[0030] FIG. 24 shows that the anti-TRGV9 / anti-BCMA bispecific antibody (VG9SB10SC1087_P18_C12-Fab RF, BCMA-scFv (BCMB519-scFv ) (BCV9B101.001)) binds gd T cells (left panel) and mediates gd T cell cytotoxicityagainst BCMA expressing H929 cells in vitro (right panel). EC50values were calculated as described in methods. Representative data shown here are from a single experiment.
[0031] FIG. 25 shows that the anti-TRGV9 / anti-BCMA bispecific antibody (VG9SB10SC1087_P19_C03-Fab RF, BCMA-scFv (BCMB519-scFv ) (BCV9B103.001)) binds gd T cells (left panel) and mediates gd T cell cytotoxicity against BCMA expressing H929 cells in vitro (right panel). EC50values were calculated as described in methods. Representative data shown here are from a single experiment.
[0032] FIG. 26 shows humanization of murine anti-Vγ9 antibody. Humanization of murine clone 7A5 was performed following the process outlined by Singh et al. , Mabs. 2015. 7:778-791. Based on sequence homology, germline IGHV1-8*01 and IGKV4-1*01 was chosen for framework adaption. A potential Iso- Asp isomerization site (DG motif) was also included in the design.
[0033] FIGS. 27A-27B show epitope and paratope mapping. FIG. 27A shows HX-MS epitope mapping for the mouse anti-human TCR Vγ9 [clone 7A5] mAh and ng9 / nd2 fused to human Fc. Sequences of VG9 (SEQ ID NO:789 (amino acids 20- 261 of SEQ ID NO: 156)) and VD2 (SEQ ID NO: 790 (amino acids 20-248 of SEQ ID NO: 157)) are shown at the bottom. The peptide region comprising amino acids 49-68 of SEQ ID NO: 789 (L49VSISYDGTVRKESGIPSGK68 (SEQ ID NO: 774) (italicized)), was protected by mAh 7A5. A molecular model (using crystal structure PBD: 1HXM, see Allison etal. , Nature. 2001. 411:820-824) of TCR ng9-nd2 and residues in the epitope are highlighted in the sphere representation. FIG. 27B shows HDX paratope mapping on the murine clone 7A5 (Vg9_7A5_VH SEQ ID NO: 7; Vg9_7A5_VL SEQ ID NO:8). A molecular model of the Fab with residues in the paratope are highlighted.
[0034] FIGS. 28A-28B show healthy individuals harbor a wide range of Vγ9 gd T cells among whole PBMCs. FIG. 28A shows the frequency of Vγ9 gd T+ + cells (TCRVγ9 CD3 ) cells among the whole PBMCs. Numbers in quadrants represent the frequency of respective population. FIG. 28B shows scatter dot plot+ graph summarizing the frequency (mean±SEM) of Vγ9 gd T cells among whole PBMCs of healthy individuals. Each dot represent data from a healthy individual.
[0035] FIGS. 29A-29C show characterisation of ng9+gd T cells. FIG. 29A, left and middle panels, show graphs summarizing the frequency of Vγ9+ gd T cells among whole PBMCs on day 0 and day 14 of culture containing Zoledronic acid that selectively activates and expands Vγ9+ gd T cells. FIG. 29A, right panel, shows representative data of n=15 donors from 6 independent experiments is shown in the graphs. Percent of Vγ9+ gd T cells among total CD3+ T cells on day 0 and 14 of activation with each dot representing the data from a donor. FIG. 29B, left two panels, shows numbers in representative FACS plots depict the differentiation profile of Vγ9+ gd T cells on day 0 and 14 of culture containing Zoledronic acid. FIG. 29B, right two panels, shows a scatter plot graph, which summarizes the frequency of Vγ9+ gd T cells positive for Naive (CD27+CD45RA+), Central memory (CD27+ CD45RA-), Effector Memory (CD27- CD45RA-) and Effector Memory cells that re expresses CD45RA (EMRA, CD27- CD45RA+) phenotypes on day 0 and 14 of culture containing Zoledronic acid. Each dot represents the data from a healthy donor. Representative data of n=13 donors from 4 independent experiments is shown in the plots. FIG. 29C shows numbers in representative FACS plots, which depict the frequency (mean ±SEM) of Vγ9+ gd T cells on day 0 (top row) and day 14 (bottom row) positive for Granzyme B and Perforin intracellular expression. Data for n=12 and n=7 donors from fresh Vγ9+ gd T cells (Day 0) and for n= 14 and n=9 donors from activated Vγ9+ gd T cells (day 14) for Granzyme B and Perforin intracellular expression respectively is presented in the figure.
[0036] FIGS. 30A-30D show anti-TRGV9 / anti-CD123 bispecific antibody binds to Vγ9+ gd T cells and CD123 expressing tumor cells. CD123 expressing target cells and PBMCs that were activated and expanded with Zoledronic acid for day 14 were incubated in the presence or absence of indicated Vγ9 bispecific and Null arm control bispecific antibodies. Bound bispecific antibody staining was assessed by flow cytometry. FIG. 30A shows the frequency of Vγ9 bispecific bound Kasumi-3 cells in 3 independent experiments for Kasumi-3 cell line. The EC50values shown in the graphs refers to mean of 3 independent experiments. FIG. 30B shows Vγ9+ gd T cells at various concentrations in 2 independent experiments with 8 healthy donors. EC50 values shown in the graphs refers to 2 healthy donors. Right and left lines reflect the indicated Vγ9 bispecific antibody and its corresponding Vγ9 null arm bispecific control antibodies respectively. EC50 values shown in the graph werederived using a 4-parameter dose-response curve with the concentration of indicated bispecific antibody on the x-axis (log scale) and specific binding on the y-axis (linear scale). FIG. 30C shows Vγ9+ gd T cells were FACS-sort depleted from Pan-T cells of whole PBMCs. Total Pan-T cells and Pan-T cells depleted of Vγ9+ gd T cells were incubated in the presence and absence of indicated bispecific antibodies at various concentrations. Representative FACS plots show the depletion efficacy of Vγ9+ gd T cells among Pan-T cells. Numbers in quadrants represent the frequency of the respective population. The binding of Vγ9 / CD123 and Vγ9 / NULL bispecific antibodies are shown at indicated concentrations to pan-T cells (Vγ9 non-depleted Pan-T cells) and pan-T cells depleted of Vγ9+ gd T cells (Vγ9 depleted Pan-T cells). FIG. 30D shows CD 123 expressing Kasumi-3 and non-expressing 22Rvl cell lines were stained with anti-CD123 monoclonal antibody. The representative overlaid histogram show the staining of CD123, isotype control and FMO control on Kasumi- 3 (left) and 22Rvl (right) cell lines (upper panels). At the bottom, the representative graphs show the binding of Vγ9 / CD123 and Vγ9 / NULL bispecific antibodies to Kasumi-3 (left) cells lines at indicated concentrations. EC50values shown in the graph were derived using a 4-parameter dose-response curve with the concentration of indicated bispecific antibody on the x-axis (log scale) and specific binding on the y-axis (linear scale).
[0037] FIGS. 31A-31F shows that Vγ9 / CD123 bispecific antibody selectively recruits, activates and induces cytotoxicity mediated by Vγ9+ gd T cells. FIG. 31A shows cell trace labelled enriched gd T cells that were co-cultured with cell trace yellow labelled kasumi-3 cells at 1:1 ET ratio in the presence of lpg / mL of indicated bispecific antibody at 37°C for 1 hour. Cell-cell association was determined using flow cytometry and quantified as double positive, cells in upper right quadrant of FACS plot. Numbers in quadrants indicate the frequency of respective population. FIGS. 31B and 31C show Pan T cells (effectors) from fresh PBMCs that were co cultured with Kasumi-3 cells (Targets) at 1 : 1 ET ratio in the presence or absence of indicated bispecific antibodies at 37°C for 72 hours. Vγ9+ gd T cells, Vγ9- gd T cells and Non- gd T cells that were positive for CD69 (left), CD25 (right) surface expression and intra cellular Granzyme B expression are shown. FIG. 31D shows Vγ9 / CD123 bispecific mediated gd T cells cytotoxicity against CD123 cells. PBMCs cultured with Zoledronic acid for 14 of (effectors) were co-cultured with CFSElabelled target (Kasumi-3) cells at ET ratio 1 : 1 (by normalizing ET ratio to Vγ9+ gd T cell frequency in expanded PBMCs) in the presence of indicated concentration of Vγ9 bispecifics and Vγ9 NULL arm control antibodies for a period of 16 hours. Target cell lysis was determined by the 7-AAD staining and flow cytometry. Graphs represent the frequency of specific target cell lysis at the indicated of concentration of Vγ9 bispecific antibodies and their respective Vγ9 / NULL arm controls. EC50values shown in representative graphs are mean of 8 healthy donors for Vγ9 / CD 123 from 3 independent experiments. FIG. 31E shows Vγ9 / CD 123 bispecific effectively mediates AML gd T cells cytotoxicity against Kasumi-3 cells. The upper and the lower lines in representative graphs show the frequency of target (kasumi-3) cell lysis (%7-AAD+cells) mediated by Vγ9 / CD 123 and Vγ9 / Null bispecific antibodies respectively, upon co-culture of day 14 Zol AML patient PBMCs with target cells for 16 hours. FIG. 31F shows the depletion efficacy of ng9+gd T cells among pan-T cells. Numbers in quadrants represent the frequency of the respective population. Graphs show the frequency of target cell lysis (% 7-AAD+cells) mediated by Vγ9 / CD 123 and Vγ9 / NULL bispecific antibodies respectively at indicated concentrations, upon co-culture of pan-T cells (Vγ9 non-depleted) and pan-T cells depleted of Vγ9+gd T cells (Vγ9 depleted) with target (Kasumi-3) cells (middle graph). Bottom graph shows the target cell lysis mediated by CD3 / CD123 and CD3 / NULL bispecific antibodies respectively at indicated concentrations.
[0038] FIGS. 32A-32C show Vγ9 / CD 123 bispecific antibody potently mediates activation, proliferation and effector functions of Vγ9+gd T cells among whole PBMCs. CFSE labelled whole PBMCs were cultured in the presence or absence kasumi-3 cells in the presence plus indicated bispecific antibodies at a concentration of 3ng / mL. FIG. 32A shows frequency of Vγ9+cells positive for surface expression of CD69 and CD25. FIG. 32B shows CFSE dilution (proliferation profile). FIG. 32C shows the ability to eliminate exogenously added Kasumi-3 cells. Each dot represent data from an individual donor. Representative data of n=5 donors from 2 independent experiments is shown in here.
[0039] FIG. 33 shows Vγ9+ gd T cell selective redirection does not elicit cytokine storm compared to Pan-T cell re-direction. Whole PBMCs were cultured in the presence or absence of spiked-in kasumi-3 cells in the presence or absence of indicated bispecific antibodies (3ng / ml) as described in FIG. 30. From day 3 ofculture onwards, 100 pL of culture medium was removed every day from the wells, without disturbing the cells, and replenished with fresh medium until day 8 of culture. Cytokines were assessed from day 3 to day 8 cell culture supernatant.FIG. 33 shows concentration of various cytokines or effector molecules in the culture supernatant of whole PBMCs stimulated with indicated bi specific antibodies. Circles and squares represent PBMCs from four individual donors stimulated with indicated bispecific antibodies or NULL arm control bispecific antibodies respectively. Representative data of n=4 donors from one independent experiment is shown here.
[0040] FIG. 34 shows mean tumor growth kinetics of NOD SCID mice bearing subcutaneous KG-1 tumor xenograft. Female NOD SCID mice inoculated subcutaneously with 1.5 x 106KG-1 cells were weekly treated subcutaneously with PBS or Vγ9Vd2 gd T cells. All mice received 15 pg / kg IL-2, and, as indicated, 1. 5 mg / kg (nb17 x DLL3). Tumor volume (left) of each mouse was measured once every three days during experimental period. Values are expressed as Mean ± SEM of 6 animals in each group. Statistical analysis carried out by Two-way ANOVA followed by Bonferroni post tests using Graph Pad Prism (Version 8.3.0). * p<0.05 & **** p<0.0001 when respective test groups were compared to Group 1- Tumor + PBS (control) group.
[0041] FIG. 35 shows binding kinetics of mouse anti-human TCR Vγ9 [clone 7A5] and recombinant Vγ9-V52-Fc antigen by SPR at 25 °C. Different concentrations of antigen (100 nM, from top to bottom in the plot) were flowed through anti-Vγ9 mAh that was captured on the surface. Experimental data (black dotted line) and 1:1 Langmuir binding fitting (smooth line) is shown. The association phase between (first -250 sec) is follow by the dissociation phase. Global fitting to a 1 : 1 simple Langmuir binding model resulted koa= 1.3 ± 0.2 x 105M1S1and k0 ff= 2.43 ± 0.3 x 104S1giving a KD = 1.9 nM.
[0042] FIGS. 36A-36D show that Vγ9+ subset of gd T cell are suitable for redirecting for tumor elimination. FIG. 36A shows the frequency (mean ±SEM) of Vg9+ gd T cells on day 0 (top row) and day 14 (bottom row) positive for activation markers. FIG. 36B shows an antigen presenting cell characteristics. FIG 36C shows exhaustion markers. FIG. 36D shows NK markers / characteristics. Representative data on n=7 donors for CD62L, CD69, CD44, 2 donors for CD45RO and CD71, 3donors for CD86, HLA-DR and CD 16, 5 donors for NKG2D, 3 donors for CD95 (Fas) surface expression on day 0 Vγ9+ gd T cells. n= 8 donors for CD62L, 9 donors for CD69 and CD44, 5 donors for CD45Ro and CD71, 3 donors for CD86, HLA-DR, CD 16, 14 donors for NKG2D, 6 donors for CD95 (Fas) surface expression on activated Vγ9+ gd T cells (day 14 n= 13 donors for PD1 and Lag3, 5 donors for CTLA4 and 2B4, 4 and 7 donors for TIGIT and Tim3 surface expression respectively on fresh Vγ9+ gd T cells (day 0). n=16 donors for PD1, 5 donors for CTLA4 and 2B4, 13 donors for Lag3, 14 donors for TIGIT surface expression on activated Vγ9+ gd T cells (day 14). >5 individual experiments were carried out.
[0043] FIGS. 37A-37B show Vγ9 bispecific binding to Vγ9+y6 T cells and TAA expressing tumor cells. Tumor Associated Antigen (TAA) expressing target cells and day 14 Zol expanded PBMCs were incubated in the presence or absence of indicated Vγ9 bispecific (Vγ9 / CD123 or Vγ9 / PSMA) and Null arm control bispecific antibodies. Bound bispecific antibody staining was assessed by flow cytometry. Representative graphs show the frequency of Vγ9 bispecific bound cells at various concentrations. Vγ9 bispecific antibody and its corresponding Vγ9 null arm bispecific control antibodies are indicated. EC50values shown in the graph were derived using a 4-parameter dose-response curve with the concentration of indicated bispecific antibody on the x-axis (log scale) and specific binding on the y-axis (linear scale). FIG. 37A shows representative data of n= 3 independent experiments for Kasumi-3, 22Rvl cell lines and FIG. 37B shows representative data of n=8 and 2 healthy donors from 2 independent experiments are shown for Vγ9 / CD123 and Vγ9 / PSMA bispecifics respectively. EC50values shown in the graphs refers to mean of 3 independent experiments (for FIG. 37A) and 9 and 2 healthy donors (for FIG. 37B).
[0044] FIGS. 38A-38B show that Vγ9 / CD123 bispecific selectively binds to Vγ9+gd T cells and CD123 expressing cell line. Vγ9+gd T cells were FACS-sort depleted from enriched Pan- T cells of whole PBMCs from healthy individuals. Total Pan-T cells and Pan-T cells depleted of Vγ9+gd T cells were incubated in the presence and absence of indicated bispecific antibodies at various concentrations. FIG. 38A depicts representative FACS plots showing the depletion efficacy of Vγ9+y6 T cells among pan-T cells. Numbers in quadrants represent the frequency of the respective population. FIG. 38A reflects the binding of Vγ9 / CD123 and Vγ9 / NULL bispecific antibodies at indicated concentrations to pan-T cells (Vγ9 non-depleted Pan-T cells)and pan-T cells depleted of Vγ9+gd T cells (Vγ9 depleted Pan-T cells). CD123 TAA expressing Kasumi-3 and non-expressing 22Rvl cell lines were stained with anti- CD123 monoclonal antibody. The upper panels of FIG. 38B show the staining of CD123, isotype control and FMO control respectively on Kasumi-3 (left) and 22Rvl (right) cell lines. The bottom panels of FIG. 38B show the binding of Vγ9 / CD123 and VY9 / NULL bispecific antibodies respectively to Kasumi-3 (left) and 22Rvl (right) cells lines at indicated concentrations. EC50values shown in the graph were derived using a 4-parameter dose-response curve with the concentration of indicated bispecific antibody on the x-axis (log scale) and specific binding on the y-axis (linear scale).
[0045] FIGS. 39A-39B show that Vγ9 bispecific mediated re-direction of gd T cells effectively eliminates liquid and solid tumors. Whole PBMCs were cultured in the presence of Zol+IL-2+Il-15 for 14 days. Vγ9+gd T cell frequency was assessed among whole PBMCs by flow cytotmetry. Day 14 Zol cultured PBMCs (effectors) were co-cultured with CFSE labelled target (Kasumi-3) cells at ET ratio 1 : 1 (for Kasumi-3 cells) and 5:1 (for 22Rvl) ET ratio (by normalizing ET ratio to Vj9 frequency in Zol expanded PBMCs) in the presence of indicated concentration of Vγ9 bispecifics and Vγ9 NULL arm control antibodies for a period of 16 hours (for Kasumi-3 targets) and 72 hours (for 22Rvl) and at 37°C in a humidified C02 incubator. Target cell lysis was determined by the 7-AAD staining and flow cytometry. Graphs shown in FIG. 39A and FIG. 39B represent the frequency of specific target cell lysis at the indicated concentration of Vγ9 bispecific antibodies and their respective VY9 / NULL arm controls. EC50values shown in representative graphs are mean of 8 and 2 healthy donors for VY9 / CD123 (FIG. 39 A) and VY9 / PSMA (FIG. 39B) bispecific antibodies respectively from 3 (for FIG. 39A) and one (for FIG. 39B) independent experiments.
[0046] FIGS. 40A-40E show that VY9 / CD123 bispecific antibody potently mediates activation, proliferation and effector functions of ng9+gd T cells among whole PBMCs. FIG. 40A shows how CFSE labelled whole PBMCs were cultured in the presence or absence of spiked-in kasumi-3 cells in the presence of indicated bispecific antibodies at a concentration of 3ng / mL. As a control, CFSE labelled whole PBMCs (with or without spiked in Kasumi-3 cells) were cultured in the absence of any bispecific antibody. FIG. 40B depicts graphs that represent the mean (±SEM)frequency of Vγ9+cells positive for surface expression of CD69, CD25 and CD71 (activation markers). FIG. 40C shows CFSE dilution (proliferation profile) and FIG. 40D shows ability to eliminate exogenously added Kasumi-3 cells or endogenous CD123+cells (as shown in FIG. 40E) among whole PBMCs (effector profile) upon culture in the absence or presence of indicated bispecific antibodies (FIGS. 40C-40E). Each dot represent data from an individual healthy donor. Representative data of n=5 donors from 2 independent experiments is shown in here.
[0047] FIGS. 41A-41C show that Vγ9+ gd T cell selective redirection do not elicit cytokine storm compared to Pan-T cell re-direction. Whole PBMCs were cultured in the presence or absence of spiked-in kasumi-3 cells in the presence or absence of indicated bispecific antibodies (3ng / ml) as described in FIG. 40. From day 3 of culture onwards, 100 pL of culture medium was removed every day from the wells, without disturbing the cells, and replenished with fresh medium until day 8 of culture. Cytokines were assessed from day 3 to day 8 cell culture supernatant. FIG. 41A, FIG. 41B and FIG. 41C show concentration of various cytokines or effector molecules in the culture supernatant of whole PBMCs stimulated with indicated bispecific antibodies. Circles and squares represent PBMCs from four individual donors stimulated with indicated bispecific antibodies or NULL arm control bispecific antibodies respectively. Representative data of n=4 donors from one independent experiment is shown here.
[0048] FIGS. 42A-42D show Vγ9 / CD123 bispecific mediated gd T cells redirection in AML patients PBMCs. FIG. 42A shows TCR Vγ9+gd T cells from AML patients can be expanded via ZoL. Numbers in representative FACS plots show the frequency of Vγ9+and Vγ9 gd T cells on day 0 (left) and day 14 (right) AML patients PBMCs culture with Zol+IL-2+IL-15. FIG. 42B shows the fold of expansion of TCRVγ9+gd T cells from four AML patients PBMCs. FIG. 42C shows TCR Vγ9+gd T cells from LC patients PBMCs exhibit more activated phenotype. Scatter dot plot graphs shows the frequency of Vγ9+gd T cells, from fresh PBMCs, positive for naive (CD27+CD45RA+), Central Memory (TCM: CD27+CD45RA ), Effector Memory (TEM: CD27 CD45RA) and Effector Memory cells that re-express CD45RA (EMRA: CD27 CD45RA+) phenotype. Each dot represented data from an a Lung Cancer patient sample. FIG. 42D shows Vγ9 / CD 123 bispecific effectively mediates AML gd T cells cytotoxicity against Kasumi-3 cells. It shows the frequency of target (kasumi-3) cell lysis (%7-AAD+cells) mediated by Vγ9 / CD 123 and VyO / Null bispecific antibodies, upon co-culture of day 14 Zol cultured healthy (left) or AML patient PBMCs (middle and right) with target cells for 16 hours. No bispecific control well values were subtracted from bispecific wells.DETAILED DESCRIPTION
[0049] Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed.
[0050] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms used herein have the meanings as set forth in the specification.
[0051] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.
[0052] Unless otherwise stated, any numerical values, such as a concentration or a concentration range described herein, are to be understood as being modified in all instances by the term “about.” Thus, a numerical value typically includes ± 10% of the recited value. For example, a concentration of 1 mg / mL includes 0.9 mg / mL to 1.1 mg / mL. Likewise, a concentration range of 1% to 10% (w / v) includes 0.9%(w / v) to 11% (w / v). As used herein, the use of a numerical range expressly includes all possible subranges, all individual numerical values within that range, including integers within such ranges and fractions of the values unless the context clearly indicates otherwise.
[0053] Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the invention.
[0054] As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains” or “containing,” or any other variation thereof, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers and are intended to be non-exclusive or open-ended. For example, a composition, a mixture, a process, a method, an article, or an apparatus that comprises a list of elements is not necessarily limited to only those elements but can include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
[0055] As used herein, the conjunctive term “and / or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and / or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or.”
[0056] As used herein, the term “consists of,” or variations such as “consist of’ or “consisting of,” as used throughout the specification and claims, indicate the inclusion of any recited integer or group of integers, but that no additional integer or group of integers can be added to the specified method, structure, or composition.
[0057] As used herein, the term “consists essentially of,” or variations such as “consist essentially of’ or “consisting essentially of,” as used throughout the specification and claims, indicate the inclusion of any recited integer or group of integers, and the optional inclusion of any recited integer or group of integers that do not materially change the basic or novel properties of the specified method, structure or composition. See M.P.E.P. § 2111.03.
[0058] As used herein, “subject” means any animal, preferably a mammal, most preferably a human. The term “mammal” as used herein, encompasses anymammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc ., more preferably a human.
[0059] It should also be understood that the terms “about,” “approximately,” “generally,” “substantially,” and like terms, used herein when referring to a dimension or characteristic of a component of the preferred invention, indicate that the described dimension / characteristic is not a strict boundary or parameter and does not exclude minor variations therefrom that are functionally the same or similar, as would be understood by one having ordinary skill in the art. At a minimum, such references that include a numerical parameter would include variations that, using mathematical and industrial principles accepted in the art ( e.g ., rounding, measurement or other systematic errors, manufacturing tolerances, etc.), would not vary the least significant digit.
[0060] The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences (e.g., anti-TRGV9 / anti-cancer-associated antigen bispecific antibodies and polynucleotides that encode them, anti- TRGV9 / anti-CD123 bispecific antibodies and polynucleotides that encode them, TRGV9 polypeptides and TRGV9 polynucleotides that encode them, CD123 polypeptides and CD 123 polynucleotides that encode them), refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.
[0061] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
[0062] Optimal alignment of sequences for comparison can be conducted, e.g, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol.Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc.Nat’l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, F.M. Ausubel et al ., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)).
[0063] Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul etal. (1997) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul etal ., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
[0064] Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
[0065] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g ., Karlin & Altschul, Proc. Nat’l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
[0066] A further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.
[0067] As used herein, the term “polynucleotide,” synonymously referred to as “nucleic acid molecule,” “nucleotides” or “nucleic acids,” refers to any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double- stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNAcharacteristic of viruses and cells. “Polynucleotide” also embraces relatively short nucleic acid chains, often referred to as oligonucleotides.
[0068] As used herein, the term “vector” is a replicon in which another nucleic acid segment can be operably inserted so as to bring about the replication or expression of the segment.
[0069] As used herein, the term “host cell” refers to a cell comprising a nucleic acid molecule of the invention. The “host cell” can be any type of cell, e.g ., a primary cell, a cell in culture, or a cell from a cell line. In one embodiment, a “host cell” is a cell transfected with a nucleic acid molecule of the invention. In another embodiment, a “host cell” is a progeny or potential progeny of such a transfected cell. A progeny of a cell may or may not be identical to the parent cell, e.g., due to mutations or environmental influences that can occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.
[0070] The term “expression” as used herein, refers to the biosynthesis of a gene product. The term encompasses the transcription of a gene into RNA. The term also encompasses translation of RNA into one or more polypeptides, and further encompasses all naturally occurring post-transcriptional and post-translational modifications. The expressed bispecific antibody can be within the cytoplasm of a host cell, into the extracellular milieu such as the growth medium of a cell culture or anchored to the cell membrane.
[0071] As used herein, the terms “peptide,” “polypeptide,” or “protein” can refer to a molecule comprised of amino acids and can be recognized as a protein by those of skill in the art. The conventional one-letter or three-letter code for amino acid residues is used herein. The terms “peptide,” “polypeptide,” and “protein” can be used interchangeably herein to refer to polymers of amino acids of any length. The polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.
[0072] The peptide sequences described herein are written according to the usual convention whereby the N-terminal region of the peptide is on the left and the C- terminal region is on the right. Although isomeric forms of the amino acids are known, it is the L-form of the amino acid that is represented unless otherwise expressly indicated.Antibodies
[0073] Provided herein are TRGV9 antibodies, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and compositions comprising the antibodies. In certain embodiments, provided are isolated TRGV9 antibodies, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies, and methods of using the antibodies to treat diseases are also provided. The antibodies disclosed herein possess one or more desirable functional properties, including but not limited to high-affinity binding to TRGV9 or high specificity to TRGV9. In certain embodiments, the antibodies disclosed herein possess the ability to treat or prevent a disease or disorder when administered to a subject alone or in combination with other therapies. In certain embodiments, the TRGV9 antibody comprises a TRGV9 antigen binding fragment. In some embodiments, the TRGV9 antibody consists of a TRGV9 antigen binding fragment. In other embodiments, the TRGV9 antibody is a multispecific TRGV9 antibody. In yet other embodiments, the multispecific TRGV9 antibody is a bispecific TRGV9 antibody. While TRGV9 antibodies are exemplified herein, it is understood that other molecules that bind to TRGV9 are also contemplated. Such molecules include other alternative binding agents, including equivalents of the antibodies and other antibody binding fragments provided herein.
[0074] Also provided herein are TRGV9 multispecific antibodies, nucleic acids and expression vectors encoding the multispecific antibodies, recombinant cells containing the vectors, and compositions comprising the multispecific antibodies. Methods of making the antibodies, and methods of using the multispecific antibodies to treat diseases, including cancer, are also provided. The antibodies disclosed herein possess one or more desirable functional properties. In some embodiments, the multispecific antibodies provided herein have high-affinity binding to TRGV9. In some embodiments, the multispecific antibodies provided herein have high-affinity binding to a second target antigen. In some embodiments, the multispecificantibodies provided herein have high specificity to TRGV9. In some embodiments, the multispecific antibodies provided herein have high specificity to a second target antigen. In some embodiments, the multispecific antibodies provided herein have the ability to treat or prevent a disease or disorder when administered alone. In some embodiments, the multispecific antibodies provided herein have the ability to treat or prevent a disease or disorder when administered in combination with other therapies. In a specific embodiment, the multispecific antibody is a bispecific antibody. In some embodiments, the TRGV9 antibody comprise an antigen binding fragment thereof.
[0075] As used herein, the term “antibody” is used in a broad sense and includes immunoglobulin or antibody molecules including human, humanized, composite and chimeric antibodies and antibody fragments that are monoclonal or polyclonal. In general, antibodies are proteins or peptide chains that exhibit binding specificity to a specific antigen. Antibody structures are well known. Immunoglobulins can be assigned to five major classes (i.e., IgA, IgD, IgE, IgG and IgM), depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub- classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4. Accordingly, the antibodies of the invention can be of any of the five major classes or corresponding sub-classes. In specific embodiments, the antibodies provided herein are IgGl,IgG2, IgG3 or IgG4. Antibody light chains of vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains. Accordingly, the antibodies provided herein can contain a kappa or lambda light chain constant domain. According to particular embodiments, the antibodies of the invention include heavy and / or light chain constant regions from rat or human antibodies.
[0076] In addition to the heavy and light constant domains, antibodies contain an antigen-binding region that is made up of a light chain variable region (VL) and a heavy chain variable region (VH), each of which contains three domains (i.e., complementarity determining regions 1 (CDR1), CDR2 and CDR3. A “CDR” refers to one of three hypervariable regions (HCDR1, HCDR2 or HCDR3) within the non- framework region of the immunoglobulin (Ig or antibody) VH b-sheet framework, or one of three hypervariable regions (LCDR1, LCDR2 or LCDR3) within the non- framework region of the antibody VL b-sheet framework. Accordingly, CDRs are variable region sequences interspersed within the framework region sequences. CDRregions are well known to those skilled in the art and have been defined by, for example, Kabat as the regions of most hypervariability within the antibody variable (V) domains (Kabat etal, J. Biol. Chem. 252:6609-6616 (1977); Kabat, A civ. Prot. Chem. 32:1-75 (1978)). CDR region sequences also have been defined structurally by Chothia as those residues that are not part of the conserved b-sheet framework, and thus are able to adapt different conformations (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). Both terminologies are well recognized in the art. CDR region sequences have also been defined by AbM, Contact and IMGT. Exemplary CDR region sequences are illustrated herein, for example, in the Sequence Listing, and tables provided in the Examples below. The positions of CDRs within a canonical antibody variable region have been determined by comparison of numerous structures (Al-Lazikani etal, J. Mol. Biol. 273:927-948 (1997); Morea et ah, Methods 20:267-279 (2000)). Because the number of residues within a hypervariable region varies in different antibodies, additional residues relative to the canonical positions are conventionally numbered with a, b, c and so forth next to the residue number in the canonical variable region numbering scheme (Al-Lazikani et ah, supra (1997)). Such nomenclature is similarly well known to those skilled in the art.
[0077] The light chain variable region CDR1 domain is interchangeably referred to herein as LCDR1 or VL CDR1. The light chain variable region CDR2 domain is interchangeably referred to herein as LCDR2 or VL CDR2. The light chain variable region CDR3 domain is interchangeably referred to herein as LCDR3 or VL CDR3. The heavy chain variable region CDR1 domain is interchangeably referred to herein as HCDR1 or VH CDR1. The heavy chain variable region CDR2 domain is interchangeably referred to herein as HCDR2 or VH CDR2. The heavy chain variable region CDR1 domain is interchangeably referred to herein as HCDR3 or VH CDR3.
[0078] The term “hypervariable region”, such as a VH or VL, when used herein refers to the regions of an antibody variable region that are hypervariable in sequence and / or form structurally defined loops. Generally, antibodies comprise six hypervariable regions; three in the VH (HCDR1, HCDR2, HCDR3), and three in the VL (LCDR1, LCDR2, LCDR3). A number of hypervariable region delineations are in use and are encompassed herein. The “Kabat” CDRs are based on sequence variability and are the most commonly used (see, e.g., Kabat etal. , Sequences ofProteins of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). “Chothia” refers instead to the location of the structural loops (see, e.g., Chothia and Lesk, . / . Mol. Biol. 196:901-917 (1987)). The end of the Chothia CDR-HCDR1 loop when numbered using the Rabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Rabat numbering scheme places the insertions at H35A and H35B; if neither 35 A nor 35B is present, the loop ends at 32; if only 35 A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The “AbM” hypervariable regions represent a compromise between the Rabat CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software (see, e.g, Martin, in Antibody Engineering. Vol. 2, Chapter 3, Springer Verlag). “Contact” hypervariable regions are based on an analysis of the available complex crystal structures.
[0079] Recently, a universal numbering system has been developed and widely adopted, ImMunoGeneTics (IMGT) Information System®(Lafranc etal. , Dev.Comp. Immunol. 27(l):55-77 (2003)). IMGT is an integrated information system specializing in immunoglobulins (IG), T cell receptors (TR) and major histocompatibility complex (MHC) of human and other vertebrates. Herein, the CDRs are referred to in terms of both the amino acid sequence and the location within the light or heavy chain. As the “location” of the CDRs within the structure of the immunoglobulin variable domain is conserved between species and present in structures called loops, by using numbering systems that align variable domain sequences according to structural features, CDR and framework residues and are readily identified. This information can be used in grafting and replacement of CDR residues from immunoglobulins of one species into an acceptor framework from, typically, a human antibody. An additional numbering system (AHon) has been developed by Honegger and Pluckthun, . / . Mol. Biol. 309: 657-670 (2001). Correspondence between the numbering system, including, for example, the Rabat numbering and the IMGT unique numbering system, is well known to one skilled in the art (see, e.g., Rabat, supra ; Chothia and Lesk, supra ; Martin, supra ; Lefranc et al. , supra). An Exemplary system, shown herein, combines Rabat and Chothia.0080] Hypervariable regions may comprise “extended hypervariable regions” as follows: 24-36 or 24-34 (LCDR1), 46-56 or 50-56 (LCDR2) and 89-97 or 89-96 (LCDR3) in the VL and 26-35 or 26-35A (HCDR1), 50-65 or 49-65 (HCDR2) and 93-102, 94-102, or 95-102 (HCDR3) in the VH. CDR sequences, reflecting each of the above numbering schemes, are provided herein, including in the Sequence Listing.
[0081] The term “constant region” or “constant domain” refers to a carboxy terminal portion of the light and heavy chain which is not directly involved in binding of the antibody to antigen but exhibits various effector function, such as interaction with the Fc receptor. The terms refer to the portion of an immunoglobulin molecule having a more conserved amino acid sequence relative to the other portion of the immunoglobulin, the variable region, which contains the antigen binding site. The constant region may contain the CHI, CH2 and CH3 regions of the heavy chain and the CL region of the light chain.
[0082] The term “framework” or “FR” residues are those variable region residues flanking the CDRs. FR residues are present, for example, in chimeric, humanized, human, domain antibodies, diabodies, linear antibodies, and bispecific antibodies. FR residues are those variable domain residues other than the hypervariable region residues or CDR residues.
[0083] As used herein, the term an “isolated antibody” refers to an antibody which is substantially free of other antibodies having different antigenic specificities ( e.g ., an isolated antibody that specifically binds to TRGV9 is substantially free of antibodies that do not bind to Vγ9; an isolated antibody that specifically binds to a second target (e.g., CD123) is substantially free of antibodies that do not bind to the second target (e.g, CD123). In addition, an isolated antibody is substantially free of other cellular material and / or chemicals.
[0084] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. The monoclonal antibodies of the invention can be made by the hybridoma method, phage display technology, single lymphocyte gene cloning technology, or by recombinant DNA methods. For example, the monoclonal antibodies can be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, such as a transgenic mouse or rat, having a genome comprising a human heavy chain transgene and a light chain transgene.
[0085] As used herein, the term “antigen-binding fragment” refers to an antibody fragment such as, for example, a diabody, a Fab, a Fab’, a F(ab’)2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv’), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), a single domain antibody (sdAb) an scFv dimer (bivalent diabody), a multispecific antibody formed from a portion of an antibody comprising one or more CDRs, a camelized single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not comprise a complete antibody structure. An antigen-binding fragment is capable of binding to the same antigen to which the parent antibody or a parent antibody fragment binds. According to particular embodiments, the antigen-binding fragment comprises a light chain variable region, a light chain constant region, and an Fd segment of the heavy chain. According to other particular embodiments, the antigen binding fragment comprises Fab and F(ab’).
[0086] As used herein, the term “single-chain antibody” refers to a conventional single-chain antibody in the field, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids. As used herein, the term “single domain antibody” refers to a conventional single domain antibody in the field, which comprises a heavy chain variable region and a heavy chain constant region or which comprises only a heavy chain variable region.
[0087] As used herein, the term “human antibody” refers to an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human made using any technique known in the art. Thisdefinition of a human antibody includes intact or full-length antibodies, fragments thereof, and / or antibodies comprising at least one human heavy and / or light chain polypeptide.
[0088] As used herein, the term “humanized antibody” refers to a non-human antibody that is modified to increase the sequence homology to that of a human antibody, such that the antigen-binding properties of the antibody are retained, but its antigenicity in the human body is reduced.
[0089] As used herein, the term “chimeric antibody” refers to an antibody wherein the amino acid sequence of the immunoglobulin molecule is derived from two or more species. The variable region of both the light and heavy chains often corresponds to the variable region of an antibody derived from one species of mammal ( e.g ., mouse, rat, rabbit, etc.) having the desired specificity, affinity, and capability, while the constant regions correspond to the sequences of an antibody derived from another species of mammal (e.g., human) to avoid eliciting an immune response in that species.
[0090] As used herein, the term “multispecific antibody” refers to an antibody that comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, the first and second epitopes do not overlap or do not substantially overlap. In an embodiment, the first and second epitopes are on different antigens, e.g, the different proteins (or different subunits of a multimeric protein). In an embodiment, a multispecific antibody comprises a third, fourth, or fifth immunoglobulin variable domain. In an embodiment, a multispecific antibody is a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule.
[0091] As used herein, the term “bispecific antibody” refers to a multispecific antibody that binds no more than two epitopes or two antigens. A bispecific antibody is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope (e.g, an epitope on a TRGV9 antigen) and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In an embodiment, the first and second epitopes are on different antigens, e.g, the different proteins (or different subunits of a multimeric protein).In an embodiment, a bispecific antibody comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In an embodiment, a bispecific antibody comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment, a bispecific antibody comprises a scFv, or fragment thereof, having binding specificity for a first epitope, and a scFv, or fragment thereof, having binding specificity for a second epitope. In an embodiment, the first epitope is located on TRGV9 and the second epitope is located on CD123. In an embodiment, the first epitope is located on TRGV9 and the second epitope is located on CD33. In an embodiment, the first epitope is located on TRGV9 and the second epitope is located on TRBC1. In an embodiment, the first epitope is located on TRGV9 and the second epitope is located on BCMA. In an embodiment, the first epitope is located on TRGV9 and the second epitope is located on PSMA. In an embodiment, the first epitope is located on TRGV9 and the second epitope is located on PD-1, PD-L1, CTLA-4, EGFR, HER-2, CD 19, CD20, CD3 and / or other cancer associated immune suppressors or surface antigens.
[0092] The term “half antibody” as used herein refers to one immunoglobulin heavy chain associated with one immunoglobulin light chain. An exemplary half antibody is depicted in SEQ ID NO: 17. One skilled in the art will readily appreciate that a half-antibody can encompass a fragment thereof and can also have an antigen binding domain consisting of a single variable domain, e.g ., originating from a camelidae.
[0093] As used herein, the term “TRGV9” refers to a polypeptide capable of forming a T cell receptor when expressed on the surface of gd T cells. TRGV9- expressing gd T cells are among the first T cells to develop in the human fetus and are the predominant gd T cell subset in healthy adult peripheral blood cells. The term “TRGV9” includes any TRGV9 variant, isoform, and species homolog, which is naturally expressed by cells (including T cells) or can be expressed on cells transfected with genes or cDNA encoding the polypeptide. In specific embodiments, the TRGV9 is a human TRGV9. An exemplary human TRGV9 amino acid sequenceis provided by GenBank Accession Number NG_001336.2. An exemplary human TRGV9 is also provided in FIG. 27A and SEQ ID NO:789.
[0094] The term “CD 123” refers to a molecule that is found on cells which helps transmit the signal of interleukin-3, a soluble cytokine that is important in the immune system. CD123 can also be referred to as the “interleukin-3 receptor.” The receptor belongs to the type I cytokine receptor family and is a heterodimer with a unique alpha chain paired with the common beta subunit (beta c or CD131). The CD123 receptor can be found on pluripotent progenitor cells and can induce tyrosine phosphorylation within the cell and promote proliferation and differentiation within hematopoietic cell lines. CD123 can also be expressed in acute myeloid leukemia (AML) subtypes. The term “CD123” includes any CD123 variant, isoform, and species homolog, which is naturally expressed by cells (including T cells) or can be expressed on cells transfected with genes or cDNA encoding those polypeptides, unless noted, in specific embodiments the “CD123” is a human CD123. A human CD123 amino acid sequence is provided by GenBank Accession Number AY789109.1.
[0095] The term “CD33” refers to a 67kD single pass transmembrane glycoprotein and is a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. While its exact biological function is unclear, in normal individuals, it is primarily considered to be a myeloid differentiation antigen, with low expression in myeloid progenitors, neutrophils and macrophages while being highly expressed in circulating monocytes and dendritic cells. CD33 has been detected on blasts and leukemic stem cells of 85-90% of patients presenting with in acute myeloid leukemia (AML). The term “CD33” includes any CD33 variant, isoform, and species homolog, which is naturally expressed by cells or can be expressed on cells transfected with genes or cDNA encoding those polypeptides, unless noted, the “CD33” is a human CD33. A human CD33 amino acid sequence is provided by GenBank Accession Number BC028152.1.
[0096] As used herein, an antibody that “specifically binds” to a target refers to an antibody that binds to a target with a KD of 1 x 10-7M or less, such as 1 x 10-8M or less, 5 x 10-9M or less, 1 x 10-9M or less, 5 x 10-10M or less, or 1x110-10M or less. In specific embodiments, the target is a human target. The target can be, e.g.,TRGV9, CD123, CD33, TRBCl, BCMA, or PSMA.
[0097] The term “KD” refers to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e., Kd / Ka) and is expressed as a molar concentration (M). KD values for antibodies can be determined using methods in the art in view of the present disclosure. For example, the KD of an antibody can be determined by using surface plasmon resonance, such as by using a biosensor system, e.g ., a Biacore® system, or by using bio-layer interferometry technology, such as an Octet RED96 system. The smaller the value of the KD of an antibody, the higher affinity that the antibody binds to a target antigen.
[0098] In one aspect, provided herein is an antibody that binds to TRGV9. In some embodiments, the antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region. In a some embodiments, the TRGV9 antibody is not a single domain antibody or nanobody. In some embodiments, the TRGV9 antibody is a humanized antibody.
[0099] In certain embodiments, provided herein is a TRGV9 antibody comprising a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 of any one of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VH region of any one of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VL region of any one of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VH region of any one of the antibodies described herein, and a VL region of any one of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VH CDR1, VH CDR2, and VH CDR3 of any one of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VL CDR1, VL CDR2, and VL CDR3 of any one of the antibodies described herein. In some embodiments, provided herein is a TRGV9 antibody comprising a VH CDR1, VH CDR2, and VH CDR3 of any one of the antibodies described herein; and a VL CDR1, VL CDR2, and VL CDR3 of any one of the antibodies described herein. Representative VH and VL amino acid sequences, including VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 amino acid sequences, of TRGV9 antibodies provided herein are provided in the Sequence Listing, as well as Tables 1-39.
[0100] In some embodiments, the TRGV9 antibody is a multispecific TRGV9 antibody provided herein. In some embodiments, the multispecific TRGV9 antibodyis a bispecific TRGV9 antibody. In one embodiment, the multispecific TRGV9 antibody comprises: (a) a first binding domain that binds to TRGV9, and (b) a second binding domain that binds to a second target that is not TRGV9.
[0101] In certain embodiments, the first binding domain that binds to TRGV9 comprises a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 of any one of the TRGV9 antibodies described herein. In some embodiments, the first binding domain that binds to TRGV9 comprises a VH region of any one of the TRGV9 antibodies described herein. In some embodiments, the first binding domain that binds to TRGV9 comprises a VL region of any one of the TRGV9 antibodies described herein. In some embodiments, the first binding domain that binds to TRGV9 comprises a VH region and a VL region of any one of the TRGV9 antibodies described herein. In some embodiments, the first binding domain that binds to TRGV9 comprises a VH CDR1, VH CDR2, and VH CDR3 of any one of the TRGV9 antibodies described herein. In some embodiments, the first binding domain that binds to TRGV9 comprises a VL CDR1, VL CDR2, and VL CDR3 of any one of the TRGV9 antibodies described herein. In some embodiments, the first binding domain that binds to TRGV9 comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of any one of the TRGV9 antibodies described herein. Representative VH and VL amino acid sequences, including VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 amino acid sequences, of TRGV9 antibodies provided herein are provided in the Sequence Listing, as well as Tables 1-39.
[0102] In some embodiments, the second target is CD 123. In some embodiments, second binding domain that binds CD 123 has a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 of a CD 123 antibody provided herein. In some embodiments, second binding domain that binds CD 123 has a VH region of a CD 123 antibody provided herein. In some embodiments, second binding domain that binds CD 123 has a VL region of a CD 123 antibody provided herein. In some embodiments, second binding domain that binds CD 123 has a VH region and a VL region of a CD 123 antibody provided herein. In some embodiments, second binding domain that binds CD123 has a VH CDR1, VH CDR2, and VH CDR3 of a CD 123 antibody provided herein. In some embodiments, second binding domain that binds CD 123 has a VL CDR1, VL CDR2, and VLCDR3 of a CD 123 antibody provided herein. In some embodiments, second bindingdomain that binds CD123 has a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a CD 123 antibody provided herein.
[0103] In some embodiments, the second target is CD33. In some embodiments, second binding domain that binds CD33 has a VH region, VL region, VH CDR1,VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 of a CD33 antibody provided herein. In some embodiments, second binding domain that binds CD33 has a VH region of a CD33 antibody provided herein. In some embodiments, second binding domain that binds CD33 has a VL region of a CD33 antibody provided herein. In some embodiments, second binding domain that binds CD33 has a VH region and a VL region of a CD33 antibody provided herein. In some embodiments, second binding domain that binds CD33 has a VH CDR1, VH CDR2, and VH CDR3 of a CD33 antibody provided herein. In some embodiments, second binding domain that binds CD33 has a VL CDR1, VL CDR2, and VL CDR3 of a CD33 antibody provided herein. In some embodiments, second binding domain that binds CD33 has a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a CD33 antibody provided herein.
[0104] In some embodiments, the second target is TRBCl. In some embodiments, second binding domain that binds TRBCl has a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 of a TRBCl antibody provided herein. In some embodiments, second binding domain that binds TRBCl has a VH region of a TRBCl antibody provided herein. In some embodiments, second binding domain that binds TRBCl has a VL region of a TRBCl antibody provided herein. In some embodiments, second binding domain that binds TRBCl has a VH region and a VL region of a TRBCl antibody provided herein. In some embodiments, second binding domain that binds TRBCl has a VH CDR1, VH CDR2, and VH CDR3 of a TRBCl antibody provided herein. In some embodiments, second binding domain that binds TRBCl has a VL CDR1, VL CDR2, and VL CDR3 of a TRBCl antibody provided herein. In some embodiments, second binding domain that binds TRBCl has a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a TRBCl antibody provided herein.
[0105] In some embodiments, the second target is BCMA. In some embodiments, second binding domain that binds BCMA has a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, V CDR2, and / or VL CDR3 of a BCMA antibody provided herein. In some embodiments, second binding domain that binds BCMAhas a VH region of a BCMA antibody provided herein. In some embodiments, second binding domain that binds BCMA has a VL region of a BCMA antibody provided herein. In some embodiments, second binding domain that binds BCMA has a VH region and a VL region of a BCMA antibody provided herein. In some embodiments, second binding domain that binds BCMA has a VH CDR1, VH CDR2, and VH CDR3 of a BCMA antibody provided herein. In some embodiments, second binding domain that binds BCMA has a VL CDR1, VL CDR2, and VL CDR3 of a BCMA antibody provided herein. In some embodiments, second binding domain that binds BCMA has a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a BCMA antibody provided herein.
[0106] In some embodiments, the second target is PSMA. In some embodiments, second binding domain that binds PSMA has a VH region, VL region, VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 of a PSMA antibody provided herein. In some embodiments, second binding domain that binds PSMA has a VH region of a PSMA antibody provided herein. In some embodiments, second binding domain that binds PSMA has a VL region of a PSMA antibody provided herein. In some embodiments, second binding domain that binds PSMA has a VH region and a VL region of a PSMA antibody provided herein. In some embodiments, second binding domain that binds PSMA has a VH CDR1, VH CDR2, and VH CDR3 of a PSMA antibody provided herein. In some embodiments, second binding domain that binds PSMA has a VL CDR1, VL CDR2, and VL CDR3 of a PSMA antibody provided herein. In some embodiments, second binding domain that binds PSMA has a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a PSMA antibody provided herein.
[0107] In some embodiments, the antibody specifically binds TRGV9. In other embodiments, the TRGV9 is present on the surface of a T cell.
[0108] In some embodiments, the TRGV9 antibody is chimeric. In some embodiments, the TRGV9 antibody is human. In some embodiments, the TRGV9 antibody is humanized. In certain embodiments, the TRGV9 antibody is an isolated TRGV9 antibody. In certain embodiments, provided is a TRGV9 antibody that is an intact antibody.
[0109] In some embodiments, the TRGV9 antibody is an IgG antibody. In some embodiments, the TRGV9 antibody is an IgGl antibody. In some embodiments, theTRGV9 antibody is an IgG2 antibody. In some embodiments, the TRGV9 antibodyis an IgG3 antibody. In some embodiments, the TRGV9 antibody is an IgG4 antibody. In some embodiments, the TRGV9 antibody comprises a kappa light chain. In some embodiments, the TRGV9 antibody comprises a lambda light chain. In some embodiments, the TRGV9 antibody is a monoclonal antibody. In some embodiments, the TRGV9 antibody is multivalent. In some embodiments, the TRGV9 antibody is capable of binding at least three antigens. In some embodiments, the TRGV9 antibody is capable of binding at least four antigens. In some embodiments, the TRGV9 antibody is capable of binding at least five antigens. In some embodiments, the TRGV9 antibody is a multispecific antibody. In some embodiments, the TRGV9 antibody is a bispecific antibody. In some embodiments, the TRGV9 antibody is a trispecific antibody. In some embodiments, the TRGV9 antibody is a quadraspecific antibody.
[0110] In other embodiments, provided is a TRGV9 antibody is an antigen binding fragment of the TRGV9 antibody. In some embodiments, the antigen binding fragment of the TRGV9 antibody is a functional fragment. In some embodiments, the TRGV9 antigen binding fragment is chimeric. In some embodiments, the TRGV9 antigen binding fragment is human. In some embodiments, a TRGV9 antigen binding fragment is humanized. In certain embodiments, a TRGV9 antigen binding fragment is an isolated TRGV9 antigen binding fragment.
[0111] In some embodiments, the antigen binding fragment is a diabody. In some embodiments, the antigen binding fragment is a Fab. In some embodiments, the antigen binding fragment is a Fab’. In some embodiments, the antigen binding fragment is a F(ab’)2. In some embodiments, the antigen binding fragment is a Fv fragment. In some embodiments, the antigen binding fragment is a disulfide stabilized Fv fragment (dsFv). In some embodiments, the antigen binding fragment is a (dsFv)2. In some embodiments, the antigen binding fragment is a bispecific dsFv (dsFv-dsFv’). In some embodiments, the antigen binding fragment is a disulfide stabilized diabody (ds diabody). In some embodiments, the antigen binding fragment is a single-chain antibody molecule (scFv). In some embodiments, the antigen binding fragment is a single domain antibody (sdAb). In some embodiments, the antigen binding fragment is an scFv dimer (bivalent diabody). In some embodiments, the antigen binding fragment is a multispecific antibody formed from a portion of an antibody comprising one or more CDRs. In some embodiments, the antigen binding fragment is a camelized single domain antibody. In some embodiments, the antigenbinding fragment is a nanobody. In some embodiments, the antigen binding fragment is a domain antibody. In some embodiments, the antigen binding fragment is a bivalent domain antibody. In some embodiments, the antigen binding fragment is an antibody fragment that binds to an antigen but does not comprise a complete antibody structure.
[0112] In some embodiments, the TRGV9 antibody is a multispecific antibody. In other embodiments, the TRGV9 antibody is a bispecific antibody. In certain embodiments, the multispecific antibody comprises an antigen binding fragment of a TRGV9 antibody provided herein. In other embodiments, the bispecific antibody comprises an antigen binding fragment of a TRGV9 antibody provided herein. In some embodiments, the TRGV9 antibody is an agonistic antibody. In certain embodiments, the TRGV9 antibody activates T cells. In other embodiments, the TRGV9 antibody is an antagonistic antibody. In certain embodiments, the TRGV9 antibody inactivates T cells. In some embodiments, the TRGV9 antibody blocks activation of T cells. In some embodiments, the TRGV9 antibody modulates the activity of T cells. In some embodiments, the TRGV9 antibody neither activates or inactivates the activity of gd T cells. In a specific embodiment, the T cells are gd T cells.
[0113] In specific embodiments, the gd T cells are human gd T cells. In specific embodiments, provided is a bispecific antibody comprising a TRGV9 antibody provided herein in a knob-in-hole format. In some embodiments, a TRGV9 antibody provided herein may be comprised in a bispecific antibody. In some embodiments, a TRGV9 bispecific antibody provided herein may be comprised in a multispecific antibody. In certain embodiments, a bispecific antibody provided herein comprises a first binding domain comprising a TRGV9 antibody provided herein that binds to a first TRGV9 epitope, and a second binding domain comprising a TRGV9 antibody provided herein that binds to a second TRGV9 epitope, wherein the first TRGV9 epitope and the second TRGV9 epitope are not the same. In a specific embodiment, a TRGV9 antibody, or antigen binding fragment thereof, provided herein specifically binds to TRGV9. In certain embodiments, a TRGV9 antibody, or antigen binding fragment thereof, provided herein does not bind to an epitope of Vb2.
[0114] In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the Rabat numbering system.In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the Exemplary numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences are according to the AbM numbering system. Exemplary sets of 6 CDRs (VH CDRl-3 and VL CDRl-3) of certain antibody embodiments are provided herein. Other sets of CDRs are contemplated and within the scope of the antibody embodiments provided herein.
[0115] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of L7A5 1 (TRGV9 1). In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:7. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:7; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:3; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VLCDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having anamino acid sequence of SEQ ID NO:6. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 160, a VH CDR2 having an amino acid sequence of SEQ ID NO: 161, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 162; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 163, a VL CDR2 having an amino acid sequence of SEQ ID NO: 164, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 165. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 166, a VH CDR2 having an amino acid sequence of SEQ ID NO: 167, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 168; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 169, a VL CDR2 having an amino acid sequence of SEQ ID NO: 170, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 171. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 172, a VH CDR2 having an amino acid sequence of SEQ ID NO: 173, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 174; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 175, a VL CDR2 having an amino acid sequence of SEQ ID NO: 176, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 177. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 178, a VH CDR2 having an amino acid sequence of SEQ ID NO: 179, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 180; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 181, a VL CDR2 having an amino acid sequence of SEQ ID NO: 182, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 183. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 178, a VH CDR2 having an amino acid sequence of SEQ ID NO:700, and a VH CDR3 having an amino acid sequence of SEQ ID NO:701; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 181, a VL CDR2 having an amino acid sequence of SEQ ID NO: 182, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 183. In another aspect, provided herein is a TRGV9 antibody, wherein the antibodycomprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 184, a VH CDR2 having an amino acid sequence of SEQ ID NO: 185, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 186; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 187, a VL CDR2 having an amino acid sequence of SEQ ID NO: 188, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 189. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 190, a VH CDR2 having an amino acid sequence of SEQ ID NO: 191, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 192; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 193, a VL CDR2 having an amino acid sequence of SEQ ID NO: 194, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 195. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:7. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 7, and a VL having an amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:23, and a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 17. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:69. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 69, and a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:7. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ IDNO:7, and a VL comprising an amino acid sequence having at least 95% identity tothe amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:23, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 17. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:69. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:24. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 69, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 24.
[0116] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of TRGV9Ab_2 (L7A5 2). In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:34. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 8. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:34; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:8. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VHCDR3 having an amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 196, a VH CDR2 having an amino acid sequence of SEQ ID NO: 197, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 198; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 199, a VL CDR2 having an amino acid sequence of SEQ ID NO:200, and a VL CDR3 having an amino acid sequence of SEQ ID NO:201. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:202, a VH CDR2 having an amino acid sequence of SEQ ID NO:203, and a VH CDR3 having an amino acid sequence of SEQ ID NO:204; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:205, a VL CDR2 having an amino acid sequence of SEQ ID NO:206, and a VL CDR3 having an amino acid sequence of SEQ ID NO:207. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:208, a VH CDR2 having an amino acid sequence of SEQ ID NO:209, and a VH CDR3 having an amino acid sequence of SEQ ID NO:210; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:211, a VL CDR2 having an amino acid sequence of SEQ ID NO:212, and a VL CDR3 having an amino acid sequence of SEQ ID NO:213. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:214, a VH CDR2 having an amino acid sequence of SEQ ID NO:215, and a VH CDR3 having an amino acid sequence of SEQ ID NO:216; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:217, a VL CDR2 having an amino acid sequence of SEQ ID NO:218, and a VL CDR3 having an amino acid sequence of SEQ ID NO:219. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:214, a VH CDR2 having an amino acid sequence of SEQ ID NO:702, and a VH CDR3 having an amino acid sequence of SEQ ID NO:703; and (ii) a VL comprising a VL CDR1 having an amino acidsequence of SEQ ID NO:217, a VL CDR2 having an amino acid sequence of SEQ ID NO:218, and a VL CDR3 having an amino acid sequence of SEQ ID NO:219. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:220, a VH CDR2 having an amino acid sequence of SEQ ID NO:221, and a VH CDR3 having an amino acid sequence of SEQ ID NO:222; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:223, a VL CDR2 having an amino acid sequence of SEQ ID NO:224, and a VL CDR3 having an amino acid sequence of SEQ ID NO:225. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:226, a VH CDR2 having an amino acid sequence of SEQ ID NO:227, and a VH CDR3 having an amino acid sequence of SEQ ID NO:228; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:229, a VL CDR2 having an amino acid sequence of SEQ ID NO:230, and a VL CDR3 having an amino acid sequence of SEQ ID NO:231. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:34. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:34, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:34. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:34, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8.
[0117] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of TRGV9Ab_3 (L7A5 3). In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:35. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VLCDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1,VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 8. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:35; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:8. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:32; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:232, a VH CDR2 having an amino acid sequence of SEQ ID NO:233, and a VH CDR3 having an amino acid sequence of SEQ ID NO:234; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:235, a VL CDR2 having an amino acid sequence of SEQ ID NO:236, and a VL CDR3 having an amino acid sequence of SEQ ID NO:237. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:238, a VH CDR2 having an amino acid sequence of SEQ ID NO:239, and a VH CDR3 having an amino acid sequence of SEQ ID NO:240; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:241, a VL CDR2 having an amino acid sequence of SEQ ID NO:242, and a VL CDR3 having an amino acid sequence of SEQ ID NO:243. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:244, a VH CDR2 having an amino acid sequence of SEQ ID NO:245, and a VH CDR3 having an amino acid sequence of SEQ ID NO:246; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:247, a VL CDR2 having an amino acid sequence of SEQ ID NO:248, and a VL CDR3 having an amino acid sequence of SEQ ID NO:249. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQID NO:250, a VH CDR2 having an amino acid sequence of SEQ ID NO:251, and a VH CDR3 having an amino acid sequence of SEQ ID NO:252; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:253, a VL CDR2 having an amino acid sequence of SEQ ID NO:254, and a VL CDR3 having an amino acid sequence of SEQ ID NO:255. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:250, a VH CDR2 having an amino acid sequence of SEQ ID NO:704, and a VH CDR3 having an amino acid sequence of SEQ ID NO:705; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:253, a VL CDR2 having an amino acid sequence of SEQ ID NO:254, and a VL CDR3 having an amino acid sequence of SEQ ID NO:255. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:256, a VH CDR2 having an amino acid sequence of SEQ ID NO:257, and a VH CDR3 having an amino acid sequence of SEQ ID NO:258; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:259, a VL CDR2 having an amino acid sequence of SEQ ID NO:260, and a VL CDR3 having an amino acid sequence of SEQ ID NO:261. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:262, a VH CDR2 having an amino acid sequence of SEQ ID NO:263, and a VH CDR3 having an amino acid sequence of SEQ ID NO:264; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:265, a VL CDR2 having an amino acid sequence of SEQ ID NO:266, and a VL CDR3 having an amino acid sequence of SEQ ID NO:267. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:35. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:35, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:35. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity tothe amino acid sequence of SEQ ID NO:35, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8.
[0118] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of TRGV9Ab_4 (L7A5 4). In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:36. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 8. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 36; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:8. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:33; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:268, a VH CDR2 having an amino acid sequence of SEQ ID NO:269, and a VH CDR3 having an amino acid sequence of SEQ ID NO:270; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:271, a VL CDR2 having an amino acid sequence of SEQ ID NO:272, and a VL CDR3 having an amino acid sequence of SEQ ID NO:273. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:274, a VH CDR2 having an amino acid sequence of SEQ ID NO:275, and a VH CDR3 having an amino acid sequence of SEQ ID NO:276; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:277, a VL CDR2 having an amino acid sequence of SEQ ID NO:278, and a VL CDR3 having an amino acidsequence of SEQ ID NO:279. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:280, a VH CDR2 having an amino acid sequence of SEQ ID NO:281, and a VH CDR3 having an amino acid sequence of SEQ ID NO:282; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:283, a VL CDR2 having an amino acid sequence of SEQ ID NO:284, and a VL CDR3 having an amino acid sequence of SEQ ID NO:285. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:286, a VH CDR2 having an amino acid sequence of SEQ ID NO:287, and a VH CDR3 having an amino acid sequence of SEQ ID NO:288; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:289, a VL CDR2 having an amino acid sequence of SEQ ID NO:290, and a VL CDR3 having an amino acid sequence of SEQ ID NO:291. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:286, a VH CDR2 having an amino acid sequence of SEQ ID NO:706, and a VH CDR3 having an amino acid sequence of SEQ ID NO:707; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:289, a VL CDR2 having an amino acid sequence of SEQ ID NO:290, and a VL CDR3 having an amino acid sequence of SEQ ID NO:291. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:292, a VH CDR2 having an amino acid sequence of SEQ ID NO:293, and a VH CDR3 having an amino acid sequence of SEQ ID NO:294; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:295, a VL CDR2 having an amino acid sequence of SEQ ID NO:296, and a VL CDR3 having an amino acid sequence of SEQ ID NO:297. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:298, a VH CDR2 having an amino acid sequence of SEQ ID NO:299, and a VH CDR3 having an amino acid sequence of SEQ ID NO:300; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:301, a VL CDR2 having an amino acid sequence of SEQ ID NO: 302, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 303. In some embodiments, the antibody comprises a VH having an amino acid sequence ofSEQ ID NO:36. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:36, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:36. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:36, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8.
[0119] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of TRGV9Ab_varl7. In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of TRGV9Ab_var29. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 65. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:66. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:66. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:67. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 68. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising aVH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VHCDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 67; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 68. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:76, and a VH CDR3 having an amino acid sequence of SEQ ID NO:3; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:77, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 60, a VH CDR2 having an amino acid sequence of SEQ ID NO:61, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 62; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:63, a VL CDR2 having an amino acid sequence of SEQ ID NO:64, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 304, a VH CDR2 having an amino acid sequence of SEQ ID NO:305, and a VH CDR3 having an amino acid sequence of SEQ ID NO:306; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 307, a VL CDR2 having an amino acid sequence of SEQ ID NO: 308, and a VL CDR3 having an amino acid sequence of SEQ ID NO:309. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 310, a VH CDR2 having an amino acid sequence of SEQ ID NO: 311, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 312; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 313, a VL CDR2 having an amino acid sequence of SEQ ID NO: 314, and a VL CDR3 having an amino acid sequence of SEQ ID NO:315. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:316, a VH CDR2 having an amino acid sequence of SEQ ID NO: 317, and a VH CDR3 having an amino acid sequence of SEQ ID NO:318; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 319, a VL CDR2 having an aminoacid sequence of SEQ ID NO:320, and a VL CDR3 having an amino acid sequence of SEQ ID NO:321. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:322, a VH CDR2 having an amino acid sequence of SEQ ID NO:323, and a VH CDR3 having an amino acid sequence of SEQ ID NO:324; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:325, a VL CDR2 having an amino acid sequence of SEQ ID NO:326, and a VL CDR3 having an amino acid sequence of SEQ ID NO:327. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:322, a VH CDR2 having an amino acid sequence of SEQ ID NO:708, and a VH CDR3 having an amino acid sequence of SEQ ID NO:709; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:325, a VL CDR2 having an amino acid sequence of SEQ ID NO:326, and a VL CDR3 having an amino acid sequence of SEQ ID NO:327. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:328, a VH CDR2 having an amino acid sequence of SEQ ID NO:329, and a VH CDR3 having an amino acid sequence of SEQ ID NO:330; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:331, a VL CDR2 having an amino acid sequence of SEQ ID NO:332, and a VL CDR3 having an amino acid sequence of SEQ ID NO:333. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:334, a VH CDR2 having an amino acid sequence of SEQ ID NO:335, and a VH CDR3 having an amino acid sequence of SEQ ID NO:336; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:337, a VL CDR2 having an amino acid sequence of SEQ ID NO:338, and a VL CDR3 having an amino acid sequence of SEQ ID NO:339. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:340, a VH CDR2 having an amino acid sequence of SEQ ID NO:341, and a VH CDR3 having an amino acid sequence of SEQ ID NO:342; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:343, a VL CDR2 having an amino acid sequence of SEQID NO:344, and a VL CDR3 having an amino acid sequence of SEQ ID NO:345. Inanother aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:346, a VH CDR2 having an amino acid sequence of SEQ ID NO:347, and a VH CDR3 having an amino acid sequence of SEQ ID NO:348; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:349, a VL CDR2 having an amino acid sequence of SEQ ID NO:350, and a VL CDR3 having an amino acid sequence of SEQ ID NO:351. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 352, a VH CDR2 having an amino acid sequence of SEQ ID NO:353, and a VH CDR3 having an amino acid sequence of SEQ ID NO:354; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:355, a VL CDR2 having an amino acid sequence of SEQ ID NO:356, and a VL CDR3 having an amino acid sequence of SEQ ID NO:357. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:358, a VH CDR2 having an amino acid sequence of SEQ ID NO:359, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 360; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:361, a VL CDR2 having an amino acid sequence of SEQ ID NO: 362, and a VL CDR3 having an amino acid sequence of SEQ ID NO:363. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:358, a VH CDR2 having an amino acid sequence of SEQ ID NO:710, and a VH CDR3 having an amino acid sequence of SEQ ID NO:711; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:361, a VL CDR2 having an amino acid sequence of SEQ ID NO: 362, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 363. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:364, a VH CDR2 having an amino acid sequence of SEQ ID NO:365, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 366; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:367, a VL CDR2 having an amino acid sequence of SEQ ID NO: 368, and a VL CDR3 having an amino acid sequence of SEQ ID NO:369. In another aspect, provided herein is aTRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1having an amino acid sequence of SEQ ID NO:370, a VH CDR2 having an amino acid sequence of SEQ ID NO:371, and a VH CDR3 having an amino acid sequence of SEQ ID NO:372; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 373, a VL CDR2 having an amino acid sequence of SEQ ID NO: 374, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:65. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:66. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:65, and a VL having an amino acid sequence of SEQ ID NO:66. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:67. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:68. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 67, and a VL having an amino acid sequence of SEQ ID NO:68. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:71. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO:72. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:71, and a light chain having an amino acid sequence of SEQ ID NO:72. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO:70. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:74. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO:75. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 74, and a light chain having an amino acid sequence of SEQ ID NO:75. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO:73. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:65. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:66. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:65, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:66. In some embodiments, the antibodycomprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:68. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:71. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:72. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:71, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:72. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO:70. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:74. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:75. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:74, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO:73.
[0120] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of VG3 B3 RN. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO:95. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:96. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VHCDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 95; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO:96. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 89, a VH CDR2 having an amino acid sequence of SEQ ID NO: 90, and a VH CDR3 having an amino acid sequence of SEQ ID NO:91; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:92, a VL CDR2 having an amino acid sequence of SEQ ID NO: 93, and a VL CDR3 having an amino acid sequence of SEQ ID NO:94. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:376, a VH CDR2 having an amino acid sequence of SEQ ID NO:377, and a VH CDR3 having an amino acid sequence of SEQ ID NO:378; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:379, a VL CDR2 having an amino acid sequence of SEQ ID NO: 380, and a VL CDR3 having an amino acid sequence of SEQ ID NO:381. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 382, a VH CDR2 having an amino acid sequence of SEQ ID NO: 383, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 384; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 385, a VL CDR2 having an amino acid sequence of SEQ ID NO: 386, and a VL CDR3 having an amino acid sequence of SEQ ID NO:387. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:388, a VH CDR2 having an amino acid sequence of SEQ ID NO: 389, and a VH CDR3 having an amino acid sequence of SEQ ID NO:390; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:391, a VL CDR2 having an amino acid sequence of SEQ ID NO: 392, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 393. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:394, a VH CDR2 having an amino acid sequence of SEQ ID NO:395, and aVH CDR3 having an amino acid sequence of SEQ ID NO: 396; and (ii) a VLcomprising a VL CDR1 having an amino acid sequence of SEQ ID NO:397, a VL CDR2 having an amino acid sequence of SEQ ID NO: 398, and a VL CDR3 having an amino acid sequence of SEQ ID NO:399. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 394, a VH CDR2 having an amino acid sequence of SEQ ID NO:712, and a VH CDR3 having an amino acid sequence of SEQ ID NO:713; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 397, a VL CDR2 having an amino acid sequence of SEQ ID NO:398, and a VL CDR3 having an amino acid sequence of SEQ ID NO:399. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:400, a VH CDR2 having an amino acid sequence of SEQ ID NO:401, and a VH CDR3 having an amino acid sequence of SEQ ID NO:402; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:403, a VL CDR2 having an amino acid sequence of SEQ ID NO:404, and a VL CDR3 having an amino acid sequence of SEQ ID NO:405. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:406, a VH CDR2 having an amino acid sequence of SEQ ID NO:407, and a VH CDR3 having an amino acid sequence of SEQ ID NO:408; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:409, a VL CDR2 having an amino acid sequence of SEQ ID NO:410, and a VL CDR3 having an amino acid sequence of SEQ ID NO:411. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:95. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:96. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:95, and a VL having an amino acid sequence of SEQ ID NO:96. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO:97. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:96. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:95, and a VL comprising anamino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:96. In some embodiments, the antibody comprises an amino acid sequence having at least 95% identity to an amino acid sequence of SEQ ID NO:97.
[0121] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of VG9B420. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 104. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 105. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 104; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 105. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 98, a VH CDR2 having an amino acid sequence of SEQ ID NO: 99, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 100; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 101, a VL CDR2 having an amino acid sequence of SEQ ID NO: 102, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 103. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:412, a VH CDR2 having an amino acid sequence of SEQ ID NO:413, and a VH CDR3 having an amino acid sequence of SEQ ID NO:414; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:415, a VL CDR2 having an amino acid sequence of SEQ ID NO:416, and a VL CDR3 having an amino acid sequence of SEQ ID NO:417. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:418, a VH CDR2 having an amino acid sequence of SEQ ID NO:419, and a VH CDR3 having an amino acid sequence of SEQ ID NO:420; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:421, a VLCDR2 having an amino acid sequence of SEQ ID NO:422, and a VL CDR3 having an amino acid sequence of SEQ ID NO:423. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:424, a VH CDR2 having an amino acid sequence of SEQ ID NO:425, and a VH CDR3 having an amino acid sequence of SEQ ID NO:426; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:427, a VL CDR2 having an amino acid sequence of SEQ ID NO:428, and a VL CDR3 having an amino acid sequence of SEQ ID NO:429. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:430, a VH CDR2 having an amino acid sequence of SEQ ID NO:431, and a VH CDR3 having an amino acid sequence of SEQ ID NO:432; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:433, a VL CDR2 having an amino acid sequence of SEQ ID NO:434, and a VL CDR3 having an amino acid sequence of SEQ ID NO:435. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:430, a VH CDR2 having an amino acid sequence of SEQ ID NO:714, and a VH CDR3 having an amino acid sequence of SEQ ID NO:715; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:433, a VL CDR2 having an amino acid sequence of SEQ ID NO:434, and a VL CDR3 having an amino acid sequence of SEQ ID NO:435. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:436, a VH CDR2 having an amino acid sequence of SEQ ID NO:437, and a VH CDR3 having an amino acid sequence of SEQ ID NO:438; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:439, a VL CDR2 having an amino acid sequence of SEQ ID NO:440, and a VL CDR3 having an amino acid sequence of SEQ ID NO:441. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:442, a VH CDR2 having an amino acid sequence of SEQ ID NO:443, and a VH CDR3 having an amino acid sequence of SEQ ID NO:444; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:445, a VL CDR2 having an amino acid sequence of SEQID NO:446, and a VL CDR3 having an amino acid sequence of SEQ ID NO:447. Insome embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 104. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 104, and a VL having an amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 106. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 104. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 104, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises an amino acid sequence of SEQ ID NO: 106.
[0122] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of VG9SB10SC1087 P18 D08. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 113. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 114. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 113; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 114. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 107, a VH CDR2 having an amino acid sequence of SEQ ID NO: 108, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 109; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ IDNO: 110, a VL CDR2 having an amino acid sequence of SEQ ID NO: 111, and a VLCDR3 having an amino acid sequence of SEQ ID NO: 112. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:448, a VH CDR2 having an amino acid sequence of SEQ ID NO:449, and a VH CDR3 having an amino acid sequence of SEQ ID NO:450; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:451, a VL CDR2 having an amino acid sequence of SEQ ID NO:452, and a VL CDR3 having an amino acid sequence of SEQ ID NO:453. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:454, a VH CDR2 having an amino acid sequence of SEQ ID NO:455, and a VH CDR3 having an amino acid sequence of SEQ ID NO:456; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:457, a VL CDR2 having an amino acid sequence of SEQ ID NO:458, and a VL CDR3 having an amino acid sequence of SEQ ID NO:459. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:460, a VH CDR2 having an amino acid sequence of SEQ ID NO:461, and a VH CDR3 having an amino acid sequence of SEQ ID NO:462; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:463, a VL CDR2 having an amino acid sequence of SEQ ID NO:464, and a VL CDR3 having an amino acid sequence of SEQ ID NO:465. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:466, a VH CDR2 having an amino acid sequence of SEQ ID NO:467, and a VH CDR3 having an amino acid sequence of SEQ ID NO:468; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:469, a VL CDR2 having an amino acid sequence of SEQ ID NO:470, and a VL CDR3 having an amino acid sequence of SEQ ID NO:471. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:466, a VH CDR2 having an amino acid sequence of SEQ ID NO:716, and a VH CDR3 having an amino acid sequence of SEQ ID NO:717; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:469, a VL CDR2 having an amino acid sequence of SEQ ID NO:470, and a VL CDR3 having an amino acid sequence of SEQ ID NO:471. In another aspect, provided herein is aTRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:472, a VH CDR2 having an amino acid sequence of SEQ ID NO:473, and a VH CDR3 having an amino acid sequence of SEQ ID NO:474; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:475, a VL CDR2 having an amino acid sequence of SEQ ID NO:476, and a VL CDR3 having an amino acid sequence of SEQ ID NO:477. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:478, a VH CDR2 having an amino acid sequence of SEQ ID NO:479, and a VH CDR3 having an amino acid sequence of SEQ ID NO:480; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:481, a VL CDR2 having an amino acid sequence of SEQ ID NO:482, and a VL CDR3 having an amino acid sequence of SEQ ID NO:483. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO:l 13. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO:l 14. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 113, and a VL having an amino acid sequence of SEQ ID NO:l 14. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO:l 15. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO: 116. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 115, and a light chain having an amino acid sequence of SEQ ID NO: 116. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 113, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 115. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least95% identity to the amino acid sequence of SEQ ID NO: 116. In some embodiments,the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 115, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 116.
[0123] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of VG9SB10SC1087 P18 C12. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 123. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 124. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 123; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 124. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 117, a VH CDR2 having an amino acid sequence of SEQ ID NO: 118, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 119; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 120, a VL CDR2 having an amino acid sequence of SEQ ID NO: 121, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 122. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:484, a VH CDR2 having an amino acid sequence of SEQ ID NO:485, and a VH CDR3 having an amino acid sequence of SEQ ID NO:486; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:487, a VL CDR2 having an amino acid sequence of SEQ ID NO:488, and a VL CDR3 having an amino acid sequence of SEQ ID NO:489. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:490, a VH CDR2 having an amino acid sequence ofSEQ ID NO:491, and a VH CDR3 having an amino acid sequence of SEQ IDNO:492; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:493, a VL CDR2 having an amino acid sequence of SEQ ID NO:494, and a VL CDR3 having an amino acid sequence of SEQ ID NO:495. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:496, a VH CDR2 having an amino acid sequence of SEQ ID NO:497, and a VH CDR3 having an amino acid sequence of SEQ ID NO:498; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:499, a VL CDR2 having an amino acid sequence of SEQ ID NO:500, and a VL CDR3 having an amino acid sequence of SEQ ID NO:501. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:502, a VH CDR2 having an amino acid sequence of SEQ ID NO:503, and a VH CDR3 having an amino acid sequence of SEQ ID NO:504; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:505, a VL CDR2 having an amino acid sequence of SEQ ID NO:506, and a VL CDR3 having an amino acid sequence of SEQ ID NO:507. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:502, a VH CDR2 having an amino acid sequence of SEQ ID NO:718, and a VH CDR3 having an amino acid sequence of SEQ ID NO:719; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:505, a VL CDR2 having an amino acid sequence of SEQ ID NO:506, and a VL CDR3 having an amino acid sequence of SEQ ID NO:507. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:508, a VH CDR2 having an amino acid sequence of SEQ ID NO:509, and a VH CDR3 having an amino acid sequence of SEQ ID NO:510; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:511, a VL CDR2 having an amino acid sequence of SEQ ID NO: 512, and a VL CDR3 having an amino acid sequence of SEQ ID NO:513. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:514, a VH CDR2 having an amino acid sequence of SEQ ID NO:515, and a VH CDR3 having an amino acid sequence of SEQ ID NO:516; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:517, a VLCDR2 having an amino acid sequence of SEQ ID NO: 518, and a VL CDR3 having an amino acid sequence of SEQ ID NO:519. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 123. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO: 124. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 123, and a VL having an amino acid sequence of SEQ ID NO: 124. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 125. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO: 126. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 125, and a light chain having an amino acid sequence of SEQ ID NO: 126. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 123, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 125. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 126. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 125, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 126.
[0124] In one aspect, a TRGV9 antibody provided herein has a VH and VL amino acid sequence of VG9SB10SC1087 P19 C03. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 133. In one aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises a VL comprising a VLCDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1,VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 134. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having amino acid sequences of the VH CDR1, VH CDR2, and VH CDR3, respectively, of SEQ ID NO: 133; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having amino acid sequences of the VL CDR1, VL CDR2, and VL CDR3, respectively, of SEQ ID NO: 134. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 127, a VH CDR2 having an amino acid sequence of SEQ ID NO: 128, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 129; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 130, a VL CDR2 having an amino acid sequence of SEQ ID NO: 131, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 132. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:520, a VH CDR2 having an amino acid sequence of SEQ ID NO: 521, and a VH CDR3 having an amino acid sequence of SEQ ID NO:522; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 523, a VL CDR2 having an amino acid sequence of SEQ ID NO: 524, and a VL CDR3 having an amino acid sequence of SEQ ID NO:525. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 526, a VH CDR2 having an amino acid sequence of SEQ ID NO: 527, and a VH CDR3 having an amino acid sequence of SEQ ID NO:528; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:529, a VL CDR2 having an amino acid sequence of SEQ ID NO:530, and a VL CDR3 having an amino acid sequence of SEQ ID NO:531. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:532, a VH CDR2 having an amino acid sequence of SEQ ID NO:533, and a VH CDR3 having an amino acid sequence of SEQ ID NO:534; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:535, a VL CDR2 having an amino acid sequence of SEQ ID NO:536, and a VL CDR3 having an amino acid sequence of SEQ ID NO:537. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 havingan amino acid sequence of SEQ ID NO:538, a VH CDR2 having an amino acid sequence of SEQ ID NO:539, and a VH CDR3 having an amino acid sequence of SEQ ID NO:540; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 541, a VL CDR2 having an amino acid sequence of SEQ ID NO: 542, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 543. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:538, a VH CDR2 having an amino acid sequence of SEQ ID NO:720, and a VH CDR3 having an amino acid sequence of SEQ ID NO:721; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:541, a VL CDR2 having an amino acid sequence of SEQ ID NO: 542, and a VL CDR3 having an amino acid sequence of SEQ ID NO:543. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 544, a VH CDR2 having an amino acid sequence of SEQ ID NO:545, and a VH CDR3 having an amino acid sequence of SEQ ID NO:546; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 547, a VL CDR2 having an amino acid sequence of SEQ ID NO:548, and a VL CDR3 having an amino acid sequence of SEQ ID NO:549. In another aspect, provided herein is a TRGV9 antibody, wherein the antibody comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:550, a VH CDR2 having an amino acid sequence of SEQ ID NO:551, and a VH CDR3 having an amino acid sequence of SEQ ID NO:552; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:553, a VL CDR2 having an amino acid sequence of SEQ ID NO: 554, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 555. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 133. In some embodiments, the antibody comprises a VL having an amino acid sequence of SEQ ID NO: 134. In some embodiments, the antibody comprises a VH having an amino acid sequence of SEQ ID NO: 133, and a VL having an amino acid sequence of SEQ ID NO: 134. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody comprises a light chain having an amino acid sequence of SEQ ID NO: 136. In some embodiments, the antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 135, and a light chain having an amino acid sequence of SEQ IDNO: 136. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 133. In some embodiments, the antibody comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the antibody comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 133, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 136. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 135, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 136.
[0125] In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the TRGV9 antibody are according to the Rabat numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the TRGV9 antibody are according to the Chothia numbering system.In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the TRGV9 antibody are according to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the TRGV9 antibody are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the TRGV9 antibody are according to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the TRGV9 antibody are according to the Exemplary numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Rabat numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Chothia numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of theTRGV9 antibody are according to the AbM numbering system. In someembodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Contact numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the IMGT numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the TRGV9 antibody are according to the Exemplary numbering system.
[0126] In some embodiments, the TRGV9 antibody is a multispecific antibody. In other embodiments, the TRGV9 antibody is a bispecific antibody. In certain embodiments, the multispecific antibody comprises an antigen binding fragment of a TRGV9 antibody provided herein. In some embodiments, the multispecific antibody comprises a first binding domain that binds to a first TRGV9 epitope and a second domain that binds to a second TRGV9 epitope, wherein the first TRGV9 epitope and the second TRGV9 epitope are different. In certain embodiments, the multispecific antibody further comprises a third binding domain that binds to a target that is not TRGV9. In some embodiments, the multispecific antibody comprises heavy chain variable regions and light chain variable region. In some embodiments, the first binding domain comprises a heavy chain variable region and a light chain variable region. In some embodiments, the second binding domain comprises a heavy chain variable region and a light chain variable region. In some embodiments, the first binding domain comprises a heavy chain variable region and a light chain variable region, and the second binding domain comprises a heavy chain variable region and a light chain variable region. In some embodiments, the first binding domain of the TRGV9 antibody is not a single domain antibody or nanobody. In a some embodiments, the second binding domain of the TRGV9 antibody is not a single domain antibody or nanobody.
[0127] In specific embodiments, the TRGV9 antibody comprises a VH region and a VL region. In some embodiments, the TRGV9 antibody is not a single chain antibody. In some embodiments, the TRGV9 antibody is not a single domain antibody. In some embodiments, the TRGV9 antibody is not a nanobody. In certain embodiments, the TRGV9 antibody is not a VHH antibody. In certain embodiments, the TRGV9 antibody is not a llama antibody. In some embodiments, the TRGV9 bispecific antibody does not comprise a single chain antibody. In some embodiments, the TRGV9 bispecific antibody does not comprise a single domain antibody. In certain embodiments, the TRGV9 bispecific antibody does not comprise a nanobody.In certain embodiments, the TRGV9 bispecific antibody does not comprise a VHH antibody. In certain embodiments, the TRGV9 bispecific antibody does not comprise a llama antibody.
[0128] In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:730, 731, and 732, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:733, 734, and 735, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:736, 737, and 738, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:739, 740, and 741, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:742,743, and 744, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:745, 746, and 747, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NOs:748,749, and 750, respectively. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:751. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:752. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:753. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:754. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:755. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:756. In some embodiments, a TRGV9 antibody provided herein does not comprise a VH domain having the amino acid sequence of SEQ ID NO:757.
[0129] In another aspect, provided herein is a TRGV9 antibody, comprising a VH domain comprising a VH CDR3 having the amino acid sequence of APNxGzYTbDF (SEQ ID NO:758), wherein x is Y or M, z is M or D, and b is I or L. In another aspect, provided herein is a TRGV9 antibody, comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 758. In another aspect, provided herein is a TRGV9 antibody, comprising a VH domain comprising a VH CDR1 having the amino acid sequence of GxTFzz (SEQ ID NO:761), wherein x is F, D or G, and z is S or N. In another aspect, provided herein is a TRGV9 antibody, comprising a VH domain comprising the amino acid sequence of SEQ ID NO:761. In another aspect, provided herein is a TRGV9 antibody, comprising a VL domain comprising a VL CDR1 having the amino acid sequence of RxSQSz (SEQ ID NO:762), wherein x is A or S, and z is V or L. In another aspect, provided herein is a TRGV9 antibody, comprising a VL domain comprising the amino acid sequence of SEQ ID NO:761.
[0130] In another aspect, provided herein is an antibody that binds to TRGV9, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3. In some embodiments, the VH CDR1 comprises a first polar amino acid. In some embodiments, the VH CDR1 comprises a last polar uncharged amino acid. In some embodiments, the VH CDR1 comprises at least one tyrosine. In some embodiments, the VH CDR1 comprises at least 20% hydrophobic amino acids. In some embodiments, the VH CDR1 comprises at least two hydrophobic amino acids. In some embodiments, the VH CDR1 comprises at least about 40% hydrophobic amino acids. In some embodiments, the VH CDR1 comprises the VH CDR1 comprises a first polar amino acid, a last polar uncharged amino acid, at least one tyrosine, at least 20% hydrophobic amino acids, at least two hydrophobic amino acids, and at least about 40% hydrophobic amino acids. Any combination of two or more of the above-mentioned VH CDR1 structural features are also contemplated. In some embodiments, the VH CDR2 comprises a polar amino acid at residue 13. In some embodiments, the VH CDR2 comprises a hydrophobic at amino acid position 15. In some embodiments, the VH CDR2 comprises a phenylalanine (F) or leucine (L) at position 15. In some embodiments, the VH CDR2 comprises a polar amino acid at position 14. In some embodiments, the VH CDR2 comprises a lysine (K) or serine (S) at position 14. In some embodiments, the VH CDR2 comprises a hydrophobic amino acid at position 2. In some embodiments, the VH CDR2 comprises ahydrophobic amino acid at position 3. In some embodiments, the VH CDR2 comprises and a polar penultimate amino acid. In some embodiments, the VH CDR2 comprises a polar amino acid at residue 13, a hydrophobic at amino acid position 15, a phenylalanine (F) or leucine (L) at position 15, a polar amino acid at position 14, a lysine (K) or serine (S) at position 14, a hydrophobic amino acid at position 2 or 3, and a polar penultimate amino acid. Any combination of two or more of the above- mentioned VH CDR2 structural features are also contemplated. In some embodiments, the VH CDR3 does not comprise a polar charged amino acid at position 3. In some embodiments, the VH CDR3 comprises a hydrophobic or polar charged amino acid at position 7. In some embodiments, the VH CDR3 comprises a polar uncharged or hydrophobic amino acid at position 6. In some embodiments, the VH CDR3 comprises no polar charged amino acid at position 3, a hydrophobic or polar charged amino acid at position 7, and a polar uncharged or hydrophobic amino acid at position 6. Any combination of two or more of the above-mentioned VH CDR3 structural features are also contemplated. In some embodiments, the VL CDR1 comprises a polar amino acid at position 4 . In some embodiments, the VL CDR1 comprises a first amino acid that is polar charged. In some embodiments, the VL CDR1 comprises a polar uncharged or hydrophobic amino acid at position 2. In some embodiments, the VL CDR1 comprises a serine at position 3. In some embodiments, the VL CDR1 comprises a polar amino acid at position 5. In some embodiments, the VL CDR1 comprises a hydrophobic amino acid at position 6. In some embodiments, the VL CDR1 comprises a polar amino acid at position 4, a first amino acid that is polar charged, a polar uncharged or hydrophobic amino acid at position 2, a serine at position 3, a polar amino acid at position 5, and a hydrophobic amino acid at position 6. Any combination of two or more of the above-mentioned VL CDR1 structural features are also contemplated. In some embodiments, the VL CDR2 comprises a polar amino acid at position 7. In some embodiments, the VL CDR2 comprises a polar charged or hydrophobic amino acid at position 6. In some embodiments, the VL CDR2 comprises a polar charged amino acid at position 3. In some embodiments, the VL CDR2 comprises a polar uncharged amino acid at position 4. In some embodiments, the VL CDR2 comprises a hydrophobic amino acid at position 2. In some embodiments, the VL CDR2 comprises a polar amino acid at position 7, a polar charged or hydrophobic amino acid at position 6, a polar charged amino acid at position 3, a polar uncharged amino acid at position 4, and ahydrophobic amino acid at position 2. Any combination of two or more of the above- mentioned VL CDR2 structural features are also contemplated. In some embodiments, the VL CDR3 comprises a hydrophobic terminal amino acid. In some embodiments, the VL CDR3 comprises a terminal tyrosine. In some embodiments, the VL CDR3 comprises a polar uncharged amino acid at position 5. In some embodiments, the VL CDR3 comprises a polar amino acid at position 2. In some embodiments, the VL CDR3 comprises a polar uncharged or hydrophobic amino acid at position 1. In some embodiments, the VL CDR3 comprises a hydrophobic amino acid at position 3. In some embodiments, the VL CDR3 comprises a hydrophilic or polar uncharged amino acid at position 6. In some embodiments, the VL CDR3 comprises no polar or hydrophobic amino acid at position 7. In some embodiments, the VL CDR3 comprises a hydrophobic terminal amino acid, a terminal tyrosine, a polar uncharged amino acid at position 5, a polar amino acid at position 2, a polar uncharged or hydrophobic amino acid at position 1, a hydrophobic amino acid at position 3, a hydrophilic or polar uncharged amino acid at position 6, and no polar or hydrophobic amino acid at position 7. Any combination of two or more of the above-mentioned VL CDR3 structural features are also contemplated. In specific embodiments, residue position numbering is according to Exemplary numbering.
[0131] In another aspect, provided herein is an antibody that binds to TRGV9, wherein the antibody comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3.
[0132] In some embodiments of the TRGV9 antibodies provided herein, the VH CDR1 comprises at least three polar amino acids. In some embodiments, the VH CDR1 comprises at least 40% polar amino acids. In some embodiments, the VH CDR1 comprises a glycine (G) at position 1. In some embodiments, the VH CDR1 does not comprise a polar uncharged amino acid at position 2. In some embodiments, the VH CDR1 comprises a polar uncharged amino acid at position 3. In some embodiments, the VH CDR1 comprises a threonine (T) or a serine (S) at position 3. In some embodiments, the VH CDR1 comprises a hydrophobic amino acid at position 4. In some embodiments, the VH CDR1 comprises a phenylalanine (F) or an isoleucine (I) at position 4. In some embodiments, the VH CDR1 comprises a polar uncharged amino acid at position 5. In some embodiments, theVH CDR1 comprises a threonine (T), a serine (S), or an asparagine (N) at position 5.In some embodiments, the VH CDR1 comprises a polar amino acid at position 6. In some embodiments, the VH CDR1 comprises an acid amino acid or a polar uncharged amino acid at position 6. In some embodiments, the VH CDR1 does not comprise a polar uncharged amino acid at position 7. Any combination of two or more of the above-mentioned VH CDR1 structural features are also contemplated. In certain embodiments, the amino acid residue numbering is according to Chothia.
[0133] In some embodiments of the TRGV9 antibodies provided herein, the VH CDR2 does not comprise a charged amino acid at position 1. In some embodiments, the VH CDR2 does not comprise a charged amino acid at position 2. In some embodiments, the VH CDR2 comprises a glycine (G), a hydrophobic, or a polar uncharged amino acid at position 2. In some embodiments, the VH CDR2 does not comprises a hydrophobic or a polar charged amino acid at position 4. In some embodiments, the VH CDR2 does not comprise a hydrophobic or a polar uncharged amino acid at the last position. In some embodiments, the VH CDR2 comprises a glycine (G) or a polar uncharged amino acid at the last position. Any combination of two or more of the above-mentioned VH CDR2 structural features are also contemplated. In certain embodiments, the amino acid residue numbering is according to Chothia.
[0134] In some embodiments of the TRGV9 antibodies provided herein, the VH CDR3 does not comprise a polar charged amino acid at position 1. In some embodiments, the VH CDR3 does not comprise a polar charged amino acid at position 2. In some embodiments, the VH CDR3 comprises a glycine (G), a tyrosine (Y), or a polar uncharged amino acid at position 2. In some embodiments, the VH CDR3 does not comprise a polar uncharged amino acid at position 3. In some embodiments, the VH CDR3 comprises a glycine (G), an aspartic acid (D), or a hydrophobic amino acid at position 3. In some embodiments, the VH CDR3 does not comprise a polar charged amino acid at position 5. In some embodiments, the VH CDR3 does not comprise a polar uncharged amino acid at position 6. In some embodiments, the VH CDR3 comprises an aspartic acid (D) or a hydrophobic amino acid at position 6. In some embodiments, the VH CDR3 comprises a hydrophobic penultimate amino acid. In some embodiments, the VH CDR3 does not comprise a polar uncharged amino acid at position 7. In some embodiments, the VH CDR3 comprises a terminal aspartic acid (D) or a terminal alanine (A). Any combination of two or more of the above-mentioned VH CDR3 structural features are alsocontemplated. In certain embodiments, the amino acid residue numbering is according to Chothia.
[0135] In some embodiments of the TRGV9 antibodies provided herein, the VL CDR1 comprises a serine (S) at position 1. In some embodiments, the VL CDR1 comprises a glutamine (G) or a glutamic acid (E) at position 2. In some embodiments, the VL CDR1 comprises a polar uncharged amino acid at position 3.In some embodiments, the VL CDR1 comprises a serine (S) or an asparagine (N) at position 3. In some embodiments, the VL CDR1 comprises a hydrophobic amino acid at position 4. In some embodiments, the VL CDR1 comprises a leucine (L), valine (V), or isoleucine (I) at position 4. In some embodiments, the VL CDR1 comprises a serine (S) or tyrosine (Y) at position 7. In some embodiments, the VL CDR1 comprises a polar uncharged penultimate amino acid. In some embodiments, the VL CDR1 comprises a terminal tyrosine (Y) or a terminal lysine (K). Any combination of two or more of the above-mentioned VL CDR1 structural features are also contemplated. In certain embodiments, the amino acid residue numbering is according to Chothia.
[0136] In some embodiments of the TRGV9 antibodies provided herein, the VL CDR2 comprises a hydrophobic amino acid at position 2. In some embodiments, the VL CDR2 comprises an alanine (A) or an isoleucine (I) at position 2. In some embodiments, the VL CDR2 comprises a polar terminal amino acid. In some embodiments, the VL CDR2 comprises a terminal serine (S) or a terminal lysine (K). Any combination of two or more of the above-mentioned VL CDR2 structural features are also contemplated. In certain embodiments, the amino acid residue numbering is according to Chothia.
[0137] In some embodiments of the TRGV9 antibodies provided herein, the VL CDR3 does not comprise a polar uncharged amino acid at position 1. In some embodiments, the VL CDR3 comprises an arginine (R) or a hydrophobic amino acid at position 1. In some embodiments, the VL CDR3 does not comprise a hydrophobic amino acid at position 3. In some embodiments, the VL CDR3 comprises an arginine (R) or a polar uncharged amino acid at position 3. In some embodiments, the VL CDR3 does not comprise a polar charged amino acid at position 4. In some embodiments, the VL CDR3 comprises a serine (S) or a hydrophobic amino acid at position 4. In some embodiments, the VL CDR3 comprises a tyrosine (Y) or a proline (P) as the penultimate amino acid. In some embodiments, the VL CDR3comprises a histidine (H) or a proline (P) at position 5. In some embodiments, the VL CDR3 comprises a terminal histidine (H), a terminal lysine (L), or a terminal tyrosine (Y). Any combination of two or more of the above-mentioned VL CDR3 structural features are also contemplated. In certain embodiments, the amino acid residue numbering is according to Chothia.
[0138] In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising a VH CDR1 having the amino acid sequence of GX1TFX2X3X4 (SEQ ID NO:777), wherein Xi is F, D, or G; X2 is T, S, or N; X3 is D, S, or N; and X4 is H, N, or Y. In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising the amino acid sequence of SEQ ID NO:777. In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising a VH CDR2 having the amino acid sequence of PGXiG (SEQ ID NO:778), wherein Xi is D or S. In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising the amino acid sequence of SEQ ID NO:778. In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising a VH CDR3 having the amino acid sequence of X1GX2YTX3D (SEQ ID NO:779), wherein Xi is Y or M, X2is D or M, and X3 is I or L. In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising the amino acid sequence of SEQ ID NO:779. In another aspect, provided herein is a TRGV9 antibody, comprising a VL comprising a VL CDR1 having the amino acid sequence of SQSX1LYSSNX2X3 (SEQ ID NO:780), wherein Xi is L or V, X2 is Q or N, and X3 is K or KNY. In another aspect, provided herein is a TRGV9 antibody, comprising a VL comprising the amino acid sequence of SEQ ID NO:780.
[0139] In another aspect, provided herein is a TRGV9 antibody, comprising a VH comprising a VH CDR1, VH CDR2 and VH CDR3. In some embodiments, the VH CDR1 comprises an amino acid sequence of GX1TFX2X3X4 (SEQ ID NO:777), wherein Xi is F, D, or G; X2 is T, S, or N; X3 is D, S, or N; and X4 is H, N, or Y. In some embodiments, the VH CDR1 comprises an amino acid sequences o SEQ ID NO: 178. In some embodiments, the VH CDR1 comprises an amino acid sequences o SEQ ID NO:394. In some embodiments, the VH CDR1 comprises an amino acid sequences o SEQ ID NO:430. In some embodiments, the VH CDR1 comprises an amino acid sequences o SEQ ID NO:466. In some embodiments, the VH CDR1 comprises an amino acid sequences o SEQ ID NO:502. In some embodiments, theVH CDR1 comprises an amino acid sequences o SEQ ID NO:538. In someembodiments, the VH CDR2 comprises an amino acid sequence of PGXiG (SEQ ID NO:778), wherein Xi is D or S. In some embodiments, the VH CDR3 comprises an amino acid sequence of X1GX2YTX3D (SEQ ID NO:779), wherein Xi is Y or M, X2 is D or M, and X3 is I or L. In another aspect, provided herein is a TRGV9 antibody, comprising a VL comprising a VL CDR1, VL CDR2 and VL CDR3. In one embodiment, the VL CDR1 comprises an amino acid sequence of SQSX1LYSSNX2X3 (SEQ ID NO:780), wherein Xi is L or V, X2 is Q or N, and X3 is K or KNY. In some embodiments, the VL CDR2 comprises an amino acid sequence of SEQ ID NO: 182. In some embodiments, the VL CDR2 comprises an amino acid sequence of SEQ ID NO: 398. In some embodiments, the VL CDR2 comprises an amino acid sequence of SEQ ID NO:434. In some embodiments, the VL CDR2 comprises an amino acid sequence of SEQ ID NO:470. In some embodiments, the VL CDR3 comprises an amino acid sequence of SEQ ID NO:542. In some embodiments, the VL CDR3 comprises an amino acid sequence of SEQ ID NO:399. In some embodiments, the VL CDR3 comprises an amino acid sequence of SEQ ID NO:435. In some embodiments, the VL CDR3 comprises an amino acid sequence of SEQ ID NO:471. In some embodiments, the VL CDR3 comprises an amino acid sequence of SEQ ID NO:507. In some embodiments, the VL CDR3 comprises an amino acid sequence of SEQ ID NO:543.
[0140] In another aspect, provided is a multispecific TRGV9 antibody, comprising a TRGV9 antibody provided herein. In some embodiments, the multispecific TRGV9 antibody is a bispecific antibody. In one aspect, provided herein is a multispecific TRGV9 antibody, wherein the antibody comprises a VH CDR1, VH CDR2 and VH CDR3 of a TRGV9 antibody provided herein. In one aspect, provided herein is a multispecific TRGV9 antibody, wherein the antibody comprises a VL CDR1, VL CDR2 and VL CDR3 of a TRGV9 antibody provided herein. In one aspect, provided herein is a multispecific TRGV9 antibody, wherein the antibody comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of a TRGV9 antibody provided herein. In one aspect, provided herein is a multispecific TRGV9 antibody, wherein the antibody comprises a VH of a TRGV9 antibody provided herein. In one aspect, provided herein is a multispecific TRGV9 antibody, wherein the antibody comprises a VL of a TRGV9 antibody provided herein. In one aspect, provided herein is a multispecific TRGV9 antibody, wherein the antibody comprises a VH and VL of a TRGV9 antibody provided herein.
[0141] In one aspect, provided herein is a multispecific TRGV9 antibody comprising: (a) a first binding domain that binds to TRGV9, and (b) a second binding domain that binds to a second target that is not TRGV9. In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is not a TRGV9 antigen. In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is not a TRGV9 epitope.
[0142] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 1 (TRGV9 1). In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:7. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:7; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:3; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 160, a VH CDR2 having an amino acid sequence of SEQ ID NO: 161, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 162; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 163, a VL CDR2 having an amino acid sequence of SEQ ID NO: 164, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 165. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1having an amino acid sequence of SEQ ID NO: 166, a VH CDR2 having an amino acid sequence of SEQ ID NO: 167, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 168; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 169, a VL CDR2 having an amino acid sequence of SEQ ID NO: 170, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 171. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 172, a VH CDR2 having an amino acid sequence of SEQ ID NO: 173, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 174; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 175, a VL CDR2 having an amino acid sequence of SEQ ID NO: 176, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 177. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 178, a VH CDR2 having an amino acid sequence of SEQ ID NO: 179, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 180; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 181, a VL CDR2 having an amino acid sequence of SEQ ID NO: 182, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 183. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 178, a VH CDR2 having an amino acid sequence of SEQ ID NO:700, and a VH CDR3 having an amino acid sequence of SEQ ID NO:701; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 181, a VL CDR2 having an amino acid sequence of SEQ ID NO: 182, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 183. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 184, a VH CDR2 having an amino acid sequence of SEQ ID NO: 185, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 186; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 187, a VL CDR2 having an amino acid sequence of SEQ ID NO: 188, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 189. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 190, a VH CDR2 having an amino acid sequence of SEQ ID NO: 191, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 192; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 193, a VLCDR2 having an amino acid sequence of SEQ ID NO: 194, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 195. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:7. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:7, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO:23. In some embodiments, the first binding domain comprises a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO:23, and a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises an amino acid sequence of SEQ ID NO: 17. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO:69. In some embodiments, the first binding domain comprises a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 69, and a light chain having an amino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:7. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:7, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:23. In some embodiments, the first binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:23, and a light chain comprising an amino acid sequence having at least 95% identity to theamino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises an amino acid sequence of SEQ ID NO: 17. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:69. In some embodiments, the first binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:24. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:69, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:24.
[0143] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 2 (TRGV9 2). In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:34. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:34; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 196, a VH CDR2 having an amino acid sequence ofSEQ ID NO: 197, and a VH CDR3 having an amino acid sequence of SEQ IDNO: 198; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 199, a VL CDR2 having an amino acid sequence of SEQ ID NO:200, and a VL CDR3 having an amino acid sequence of SEQ ID NO:201. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:202, a VH CDR2 having an amino acid sequence of SEQ ID NO:203, and a VH CDR3 having an amino acid sequence of SEQ ID NO:204; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:205, a VL CDR2 having an amino acid sequence of SEQ ID NO:206, and a VL CDR3 having an amino acid sequence of SEQ ID NO:207. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:208, a VH CDR2 having an amino acid sequence of SEQ ID NO:209, and a VH CDR3 having an amino acid sequence of SEQ ID NO:210; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:211, a VL CDR2 having an amino acid sequence of SEQ ID NO:212, and a VL CDR3 having an amino acid sequence of SEQ ID NO:213. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:214, a VH CDR2 having an amino acid sequence of SEQ ID NO:215, and a VH CDR3 having an amino acid sequence of SEQ ID NO:216; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:217, a VL CDR2 having an amino acid sequence of SEQ ID NO:218, and a VL CDR3 having an amino acid sequence of SEQ ID NO:219. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:214, a VH CDR2 having an amino acid sequence of SEQ ID NO:702, and a VH CDR3 having an amino acid sequence of SEQ ID NO:703; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:217, a VL CDR2 having an amino acid sequence of SEQ ID NO:218, and a VL CDR3 having an amino acid sequence of SEQ ID NO:219. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:220, a VH CDR2 having an amino acid sequence of SEQ ID NO:221, and a VH CDR3 having an amino acid sequence of SEQ ID NO:222; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:223, a VL CDR2 having an amino acid sequence of SEQ ID NO:224, and a VL CDR3 having an amino acid sequence of SEQ ID NO:225. In one embodiment, the first bindingdomain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:226, a VH CDR2 having an amino acid sequence of SEQ ID NO:227, and a VH CDR3 having an amino acid sequence of SEQ ID NO:228; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:229, a VL CDR2 having an amino acid sequence of SEQ ID NO:230, and a VL CDR3 having an amino acid sequence of SEQ ID NO:231. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:34. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:34, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:34. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:34, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:8.
[0144] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 3 (TRGV9 3). In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:35. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:35; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In oneembodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:32; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:232, a VH CDR2 having an amino acid sequence of SEQ ID NO:233, and a VH CDR3 having an amino acid sequence of SEQ ID NO:234; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:235, a VL CDR2 having an amino acid sequence of SEQ ID NO:236, and a VL CDR3 having an amino acid sequence of SEQ ID NO:237. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:238, a VH CDR2 having an amino acid sequence of SEQ ID NO:239, and a VH CDR3 having an amino acid sequence of SEQ ID NO:240; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:241, a VL CDR2 having an amino acid sequence of SEQ ID NO:242, and a VL CDR3 having an amino acid sequence of SEQ ID NO:243. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:244, a VH CDR2 having an amino acid sequence of SEQ ID NO:245, and a VH CDR3 having an amino acid sequence of SEQ ID NO:246; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:247, a VL CDR2 having an amino acid sequence of SEQ ID NO:248, and a VL CDR3 having an amino acid sequence of SEQ ID NO:249. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:250, a VH CDR2 having an amino acid sequence of SEQ ID NO:251, and a VH CDR3 having an amino acid sequence of SEQ ID NO:252; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:253, a VL CDR2 having an amino acid sequence of SEQ ID NO:254, and a VL CDR3 having an amino acid sequence of SEQ ID NO:255. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:250, a VH CDR2 having an amino acid sequence of SEQ ID NO:704, and a VH CDR3 having an amino acid sequence of SEQ ID NO:705; and (ii) a VL comprising a VLCDR1 having an amino acid sequence of SEQ ID NO:253, a VL CDR2 having an amino acid sequence of SEQ ID NO:254, and a VL CDR3 having an amino acid sequence of SEQ ID NO:255. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:256, a VH CDR2 having an amino acid sequence of SEQ ID NO:257, and a VH CDR3 having an amino acid sequence of SEQ ID NO:258; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:259, a VL CDR2 having an amino acid sequence of SEQ ID NO:260, and a VL CDR3 having an amino acid sequence of SEQ ID NO:261. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:262, a VH CDR2 having an amino acid sequence of SEQ ID NO:263, and a VH CDR3 having an amino acid sequence of SEQ ID NO:264; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:265, a VL CDR2 having an amino acid sequence of SEQ ID NO:266, and a VL CDR3 having an amino acid sequence of SEQ ID NO:267. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:35. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:35, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:35. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:35, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:8.
[0145] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of L7A5 4 (TRGV9 4). In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:36. In one embodiment, thefirst binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:36; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 8. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:2, and a VH CDR3 having an amino acid sequence of SEQ ID NO:33; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:4, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:268, a VH CDR2 having an amino acid sequence of SEQ ID NO:269, and a VH CDR3 having an amino acid sequence of SEQ ID NO:270; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:271, a VL CDR2 having an amino acid sequence of SEQ ID NO:272, and a VL CDR3 having an amino acid sequence of SEQ ID NO:273. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:274, a VH CDR2 having an amino acid sequence of SEQ ID NO:275, and a VH CDR3 having an amino acid sequence of SEQ ID NO:276; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:277, a VL CDR2 having an amino acid sequence of SEQ ID NO:278, and a VL CDR3 having an amino acid sequence of SEQ ID NO:279. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:280, a VH CDR2 having an amino acid sequence of SEQ ID NO:281, and a VH CDR3 having an amino acid sequence of SEQ ID NO:282; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:283, a VL CDR2 having an amino acid sequence of SEQ ID NO:284, and a VL CDR3 having an amino acid sequence of SEQ IDNO:285. In one embodiment, the first binding domain comprises: (i) a VHcomprising a VH CDR1 having an amino acid sequence of SEQ ID NO:286, a VH CDR2 having an amino acid sequence of SEQ ID NO:287, and a VH CDR3 having an amino acid sequence of SEQ ID NO:288; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:289, a VL CDR2 having an amino acid sequence of SEQ ID NO:290, and a VL CDR3 having an amino acid sequence of SEQ ID NO:291. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:286, a VH CDR2 having an amino acid sequence of SEQ ID NO:706, and a VH CDR3 having an amino acid sequence of SEQ ID NO:707; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:289, a VL CDR2 having an amino acid sequence of SEQ ID NO:290, and a VL CDR3 having an amino acid sequence of SEQ ID NO:291. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:292, a VH CDR2 having an amino acid sequence of SEQ ID NO:293, and a VH CDR3 having an amino acid sequence of SEQ ID NO:294; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:295, a VL CDR2 having an amino acid sequence of SEQ ID NO:296, and a VL CDR3 having an amino acid sequence of SEQ ID NO:297. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:298, a VH CDR2 having an amino acid sequence of SEQ ID NO:299, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 300; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:301, a VL CDR2 having an amino acid sequence of SEQ ID NO: 302, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 303. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:36. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:36, and a VL having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:36. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the first binding domain comprises a VH comprising an amino acidsequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 36, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 8.
[0146] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of TRGV9Ab_varl7. In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 65. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:66. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:66. In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain comprises a VH and VL amino acid sequence of TRGV9Ab_var29. In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:67. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 68. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 67; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 68. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequenceof SEQ ID NO: 1, a VH CDR2 having an amino acid sequence of SEQ ID NO:76, and a VH CDR3 having an amino acid sequence of SEQ ID NO:3; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:77, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 60, a VH CDR2 having an amino acid sequence of SEQ ID NO:61, and a VH CDR3 having an amino acid sequence of SEQ ID NO:62; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:63, a VL CDR2 having an amino acid sequence of SEQ ID NO: 64, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:304, a VH CDR2 having an amino acid sequence of SEQ ID NO:305, and a VH CDR3 having an amino acid sequence of SEQ ID NO:306; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:307, a VL CDR2 having an amino acid sequence of SEQ ID NO: 308, and a VL CDR3 having an amino acid sequence of SEQ ID NO:309. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 310, a VH CDR2 having an amino acid sequence of SEQ ID NO: 311, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 312; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 313, a VL CDR2 having an amino acid sequence of SEQ ID NO: 314, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 315. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 316, a VH CDR2 having an amino acid sequence of SEQ ID NO: 317, and a VH CDR3 having an amino acid sequence of SEQ ID NO:318; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:319, a VL CDR2 having an amino acid sequence of SEQ ID NO:320, and a VL CDR3 having an amino acid sequence of SEQ ID NO:321. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:322, a VH CDR2 having an amino acid sequence of SEQ ID NO:323, and a VH CDR3 having an amino acid sequence of SEQ ID NO:324; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 325, a VLCDR2 having an amino acid sequence of SEQ ID NO:326, and a VL CDR3 havingan amino acid sequence of SEQ ID NO:327. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:322, a VH CDR2 having an amino acid sequence of SEQ ID NO:708, and a VH CDR3 having an amino acid sequence of SEQ ID NO:709; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 325, a VL CDR2 having an amino acid sequence of SEQ ID NO:326, and a VL CDR3 having an amino acid sequence of SEQ ID NO:327. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:328, a VH CDR2 having an amino acid sequence of SEQ ID NO:329, and a VH CDR3 having an amino acid sequence of SEQ ID NO:330; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:331, a VL CDR2 having an amino acid sequence of SEQ ID NO:332, and a VL CDR3 having an amino acid sequence of SEQ ID NO:333. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:334, a VH CDR2 having an amino acid sequence of SEQ ID NO:335, and a VH CDR3 having an amino acid sequence of SEQ ID NO:336; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:337, a VL CDR2 having an amino acid sequence of SEQ ID NO:338, and a VL CDR3 having an amino acid sequence of SEQ ID NO:339. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:340, a VH CDR2 having an amino acid sequence of SEQ ID NO:341, and a VH CDR3 having an amino acid sequence of SEQ ID NO:342; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:343, a VL CDR2 having an amino acid sequence of SEQ ID NO:344, and a VL CDR3 having an amino acid sequence of SEQ ID NO:345. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:346, a VH CDR2 having an amino acid sequence of SEQ ID NO:347, and a VH CDR3 having an amino acid sequence of SEQ ID NO:348; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:349, a VL CDR2 having an amino acid sequence of SEQ ID NO:350, and a VL CDR3 having an amino acid sequence of SEQ ID NO:351. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:352, a VH CDR2 having an amino acid sequence of SEQ ID NO:353, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 354; and (ii) a VLcomprising a VL CDR1 having an amino acid sequence of SEQ ID NO:355, a VL CDR2 having an amino acid sequence of SEQ ID NO:356, and a VL CDR3 having an amino acid sequence of SEQ ID NO:357. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:358, a VH CDR2 having an amino acid sequence of SEQ ID NO:359, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 360; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:361, a VL CDR2 having an amino acid sequence of SEQ ID NO: 362, and a VL CDR3 having an amino acid sequence of SEQ ID NO:363. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:358, a VH CDR2 having an amino acid sequence of SEQ ID NO:710, and a VH CDR3 having an amino acid sequence of SEQ ID NO:711; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:361, a VL CDR2 having an amino acid sequence of SEQ ID NO: 362, and a VL CDR3 having an amino acid sequence of SEQ ID NO:363. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:364, a VH CDR2 having an amino acid sequence of SEQ ID NO:365, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 366; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:367, a VL CDR2 having an amino acid sequence of SEQ ID NO: 368, and a VL CDR3 having an amino acid sequence of SEQ ID NO:369. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:370, a VH CDR2 having an amino acid sequence of SEQ ID NO:371, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 372; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 373, a VL CDR2 having an amino acid sequence of SEQ ID NO: 374, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 375. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:65. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO:66. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:65, and a VL having an amino acid sequence of SEQ ID NO:66. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:67. In some embodiments, the first binding domain comprises a VL having an amino acidsequence of SEQ ID NO: 68. In some embodiments, the first binding domain a VH having an amino acid sequence of SEQ ID NO: 67, and a VL having an amino acid sequence of SEQ ID NO: 68. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO:71. In some embodiments, the first binding domain comprises a light chain having an amino acid sequence of SEQ ID NO:72. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO:71, and a light chain having an amino acid sequence of SEQ ID NO:72. In some embodiments, the first binding domain comprises an amino acid sequence of SEQ ID NO:70. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO:74. In some embodiments, the first binding domain comprises a light chain having an amino acid sequence of SEQ ID NO:75. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 74, and a light chain having an amino acid sequence of SEQ ID NO: 75. In some embodiments, the first binding domain comprises an amino acid sequence of SEQ ID NO:73. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:66. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:65, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:66. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the first binding domain a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 67, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:71. In some embodiments, thefirst binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:72. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:71, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:72. In some embodiments, the first binding domain comprises an amino acid sequence having at least 95% identity to an amino acid sequence of SEQ ID NO:70. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:74. In some embodiments, the first binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:74, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 75. In some embodiments, the first binding domain comprises an amino acid sequence having at least 95% identity to an amino acid sequence of SEQ ID NO:73.
[0147] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9 B3 RN. In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:95. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:96. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:95; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:96. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1having an amino acid sequence of SEQ ID NO: 89, a VH CDR2 having an amino acid sequence of SEQ ID NO:90, and a VH CDR3 having an amino acid sequence of SEQ ID NO:91; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 92, a VL CDR2 having an amino acid sequence of SEQ ID NO:93, and a VL CDR3 having an amino acid sequence of SEQ ID NO:94. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:376, a VH CDR2 having an amino acid sequence of SEQ ID NO:377, and a VH CDR3 having an amino acid sequence of SEQ ID NO:378; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:379, a VL CDR2 having an amino acid sequence of SEQ ID NO: 380, and a VL CDR3 having an amino acid sequence of SEQ ID NO:381. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:382, a VH CDR2 having an amino acid sequence of SEQ ID NO: 383, and a VH CDR3 having an amino acid sequence of SEQ ID NO:384; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:385, a VL CDR2 having an amino acid sequence of SEQ ID NO: 386, and a VL CDR3 having an amino acid sequence of SEQ ID NO:387. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:388, a VH CDR2 having an amino acid sequence of SEQ ID NO: 389, and a VH CDR3 having an amino acid sequence of SEQ ID NO:390; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:391, a VL CDR2 having an amino acid sequence of SEQ ID NO: 392, and a VL CDR3 having an amino acid sequence of SEQ ID NO:393. . In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:394, a VH CDR2 having an amino acid sequence of SEQ ID NO:395, and a VH CDR3 having an amino acid sequence of SEQ ID NO:396; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:397, a VL CDR2 having an amino acid sequence of SEQ ID NO: 398, and a VL CDR3 having an amino acid sequence of SEQ ID NO:399. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 394, a VH CDR2 having an amino acid sequence of SEQ ID NO:712, and a VH CDR3 having an amino acid sequence of SEQ ID NO:713; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:397, a VLCDR2 having an amino acid sequence of SEQ ID NO: 398, and a VL CDR3 having an amino acid sequence of SEQ ID NO:399. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:400, a VH CDR2 having an amino acid sequence of SEQ ID NO:401, and a VH CDR3 having an amino acid sequence of SEQ ID NO:402; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:403, a VL CDR2 having an amino acid sequence of SEQ ID NO:404, and a VL CDR3 having an amino acid sequence of SEQ ID NO:405. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:406, a VH CDR2 having an amino acid sequence of SEQ ID NO:407, and a VH CDR3 having an amino acid sequence of SEQ ID NO:408; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:409, a VL CDR2 having an amino acid sequence of SEQ ID NO:410, and a VL CDR3 having an amino acid sequence of SEQ ID NO:411. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:95. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO:96. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO:95, and a VL having an amino acid sequence of SEQ ID NO:96. In some embodiments, the first binding domain comprises an amino acid sequence of SEQ ID NO:97. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:96. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:95, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:96. In some embodiments, the first binding domain comprises an amino acid sequence having at least 95% identity to an amino acid sequence of SEQ ID NO:97.
[0148] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9B420. In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acidsequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 104. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 105. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 104; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 105. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 98, a VH CDR2 having an amino acid sequence of SEQ ID NO:99, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 100, and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 101, a VL CDR2 having an amino acid sequence of SEQ ID NO: 102, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 103. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:412, a VH CDR2 having an amino acid sequence of SEQ ID NO:413, and a VH CDR3 having an amino acid sequence of SEQ ID NO:414; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:415, a VL CDR2 having an amino acid sequence of SEQ ID NO:416, and a VL CDR3 having an amino acid sequence of SEQ ID NO:417. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:418, a VH CDR2 having an amino acid sequence of SEQ ID NO:419, and a VH CDR3 having an amino acid sequence of SEQ ID NO:420; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:421, a VL CDR2 having an amino acid sequence of SEQ ID NO:422, and a VL CDR3 having an amino acid sequence of SEQ ID NO:423. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:424, a VH CDR2 having an amino acid sequence of SEQ ID NO:425, and a VH CDR3 having an amino acid sequence of SEQ ID NO:426; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:427, a VL CDR2 having anamino acid sequence of SEQ ID NO:428, and a VL CDR3 having an amino acid sequence of SEQ ID NO:429. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:430, a VH CDR2 having an amino acid sequence of SEQ ID NO:431, and a VH CDR3 having an amino acid sequence of SEQ ID NO:432; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:433, a VL CDR2 having an amino acid sequence of SEQ ID NO:434, and a VL CDR3 having an amino acid sequence of SEQ ID NO:435. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:430, a VH CDR2 having an amino acid sequence of SEQ ID NO:714, and a VH CDR3 having an amino acid sequence of SEQ ID NO:715; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:433, a VL CDR2 having an amino acid sequence of SEQ ID NO:434, and a VL CDR3 having an amino acid sequence of SEQ ID NO:435. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:436, a VH CDR2 having an amino acid sequence of SEQ ID NO:437, and a VH CDR3 having an amino acid sequence of SEQ ID NO:438; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:439, a VL CDR2 having an amino acid sequence of SEQ ID NO:440, and a VL CDR3 having an amino acid sequence of SEQ ID NO:441. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:442, a VH CDR2 having an amino acid sequence of SEQ ID NO:443, and a VH CDR3 having an amino acid sequence of SEQ ID NO:444; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 445, a VL CDR2 having an amino acid sequence of SEQ ID NO:446, and a VL CDR3 having an amino acid sequence of SEQ ID NO:447. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 104. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 105. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 104, and a VL having an amino acid sequence of SEQ ID NO: 105. In some embodiments, the first binding domain comprises an amino acid sequence of SEQ ID NO: 106. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ IDNO: 104. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 104, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 105. In some embodiments, the first binding domain comprises an amino acid sequence having at least 95% identity to an amino acid sequence of SEQ ID NO: 106.
[0149] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9SB10SC1087 P18 D08. In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 113. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 114. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 113; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 114. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 107, a VH CDR2 having an amino acid sequence of SEQ ID NO: 108, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 109, and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 110, a VL CDR2 having an amino acid sequence of SEQ ID NO: 111, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 112. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:448, a VH CDR2 having an amino acid sequence of SEQ ID NO:449, and a VH CDR3 having an amino acid sequence of SEQ ID NO:450; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 451, a VLCDR2 having an amino acid sequence of SEQ ID NO:452, and a VL CDR3 having an amino acid sequence of SEQ ID NO:453. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:454, a VH CDR2 having an amino acid sequence of SEQ ID NO:455, and a VH CDR3 having an amino acid sequence of SEQ ID NO:456; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:457, a VL CDR2 having an amino acid sequence of SEQ ID NO:458, and a VL CDR3 having an amino acid sequence of SEQ ID NO:459. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:460, a VH CDR2 having an amino acid sequence of SEQ ID NO:461, and a VH CDR3 having an amino acid sequence of SEQ ID NO:462; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:463, a VL CDR2 having an amino acid sequence of SEQ ID NO:464, and a VL CDR3 having an amino acid sequence of SEQ ID NO:465. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:466, a VH CDR2 having an amino acid sequence of SEQ ID NO:467, and a VH CDR3 having an amino acid sequence of SEQ ID NO:468; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:469, a VL CDR2 having an amino acid sequence of SEQ ID NO:470, and a VL CDR3 having an amino acid sequence of SEQ ID NO:471. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:466, a VH CDR2 having an amino acid sequence of SEQ ID NO:716, and a VH CDR3 having an amino acid sequence of SEQ ID NO:717; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:469, a VL CDR2 having an amino acid sequence of SEQ ID NO:470, and a VL CDR3 having an amino acid sequence of SEQ ID NO:471. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:472, a VH CDR2 having an amino acid sequence of SEQ ID NO:473, and a VH CDR3 having an amino acid sequence of SEQ ID NO:474; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:475, a VL CDR2 having an amino acid sequence of SEQ ID NO:476, and a VL CDR3 having an amino acid sequence of SEQ ID NO:477. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:478, a VH CDR2 having an amino acid sequence of SEQ ID NO:479,and a VH CDR3 having an amino acid sequence of SEQ ID NO:480; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 481, a VL CDR2 having an amino acid sequence of SEQ ID NO:482, and a VL CDR3 having an amino acid sequence of SEQ ID NO:483. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 113. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 114. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 113, and a VL having an amino acid sequence of SEQ ID NO:l 14. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 115. In some embodiments, the first binding domain comprises a light chain having an amino acid sequence of SEQ ID NO:l 16. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 115, and a light chain having an amino acid sequence of SEQ ID NO: 116. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 113, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 115. In some embodiments, the first binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 116. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 115, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 116.
[0150] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9SB10SC1087 P18 C12. In one embodiment, the first bindingdomain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 123. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 124. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 123; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 124. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 117, a VH CDR2 having an amino acid sequence of SEQ ID NO: 118, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 119, and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 120, a VL CDR2 having an amino acid sequence of SEQ ID NO: 121, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 122. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:484, a VH CDR2 having an amino acid sequence of SEQ ID NO:485, and a VH CDR3 having an amino acid sequence of SEQ ID NO:486; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:487, a VL CDR2 having an amino acid sequence of SEQ ID NO:488, and a VL CDR3 having an amino acid sequence of SEQ ID NO:489. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:490, a VH CDR2 having an amino acid sequence of SEQ ID NO:491, and a VH CDR3 having an amino acid sequence of SEQ ID NO:492; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:493, a VL CDR2 having an amino acid sequence of SEQ ID NO:494, and a VL CDR3 having an amino acid sequence of SEQ ID NO:495. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:496, a VH CDR2 having an amino acid sequence of SEQ ID NO:497, and a VH CDR3 having an amino acid sequence of SEQ ID NO:498; and (ii) a VLcomprising a VL CDR1 having an amino acid sequence of SEQ ID NO:499, a VL CDR2 having an amino acid sequence of SEQ ID NO:500, and a VL CDR3 having an amino acid sequence of SEQ ID NO:501. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:502, a VH CDR2 having an amino acid sequence of SEQ ID NO:503, and a VH CDR3 having an amino acid sequence of SEQ ID NO:504; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 505, a VL CDR2 having an amino acid sequence of SEQ ID NO:506, and a VL CDR3 having an amino acid sequence of SEQ ID NO:507. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:502, a VH CDR2 having an amino acid sequence of SEQ ID NO:718, and a VH CDR3 having an amino acid sequence of SEQ ID NO:719; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 505, a VL CDR2 having an amino acid sequence of SEQ ID NO:506, and a VL CDR3 having an amino acid sequence of SEQ ID NO:507. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:508, a VH CDR2 having an amino acid sequence of SEQ ID NO:509, and a VH CDR3 having an amino acid sequence of SEQ ID NO:510; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 511, a VL CDR2 having an amino acid sequence of SEQ ID NO: 512, and a VL CDR3 having an amino acid sequence of SEQ ID NO:513. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:514, a VH CDR2 having an amino acid sequence of SEQ ID NO:515, and a VH CDR3 having an amino acid sequence of SEQ ID NO:516; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:517, a VL CDR2 having an amino acid sequence of SEQ ID NO: 518, and a VL CDR3 having an amino acid sequence of SEQ ID NO:519. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 123. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 124. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 123, and a VL having an amino acid sequence of SEQ ID NO: 124. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ IDNO: 125. In some embodiments, the first binding domain comprises a light chainhaving an amino acid sequence of SEQ ID NO: 126. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 125, and a light chain having an amino acid sequence of SEQ ID NO: 126. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 123, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 124. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 125. In some embodiments, the first binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 126. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 125, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 126.
[0151] In one embodiment of a multispecific TRGV9 antibody provided herein, the first binding domain that binds to TRGV9 comprises a VH and VL amino acid sequence of VG9SB10SC1087 P19 C03. In one embodiment, the first binding domain comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 133. In one embodiment, the first binding domain comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 134. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 133; and (ii) a VL comprising a VLCDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1,a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 134. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 127, a VH CDR2 having an amino acid sequence of SEQ ID NO: 128, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 129, and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 130, a VL CDR2 having an amino acid sequence of SEQ ID NO: 131, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 132. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 520, a VH CDR2 having an amino acid sequence of SEQ ID NO: 521, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 522; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:523, a VL CDR2 having an amino acid sequence of SEQ ID NO: 524, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 525. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO: 526, a VH CDR2 having an amino acid sequence of SEQ ID NO: 527, and a VH CDR3 having an amino acid sequence of SEQ ID NO:528; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:529, a VL CDR2 having an amino acid sequence of SEQ ID NO:530, and a VL CDR3 having an amino acid sequence of SEQ ID NO:531. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:532, a VH CDR2 having an amino acid sequence of SEQ ID NO:533, and a VH CDR3 having an amino acid sequence of SEQ ID NO:534; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 535, a VL CDR2 having an amino acid sequence of SEQ ID NO:536, and a VL CDR3 having an amino acid sequence of SEQ ID NO:537. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:538, a VH CDR2 having an amino acid sequence of SEQ ID NO:539, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 540; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 541, a VL CDR2 having an amino acid sequence of SEQ ID NO: 542, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 543. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:538, a VH CDR2 having an amino acid sequence of SEQ ID NO:720,and a VH CDR3 having an amino acid sequence of SEQ ID NO: 721; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 541, a VL CDR2 having an amino acid sequence of SEQ ID NO: 542, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 543. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:544, a VH CDR2 having an amino acid sequence of SEQ ID NO:545, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 546; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:547, a VL CDR2 having an amino acid sequence of SEQ ID NO: 548, and a VL CDR3 having an amino acid sequence of SEQ ID NO:549. In one embodiment, the first binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:550, a VH CDR2 having an amino acid sequence of SEQ ID NO:551, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 552; and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 553, a VL CDR2 having an amino acid sequence of SEQ ID NO: 554, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 555. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 133. In some embodiments, the first binding domain comprises a VL having an amino acid sequence of SEQ ID NO: 134. In some embodiments, the first binding domain comprises a VH having an amino acid sequence of SEQ ID NO: 133, and a VL having an amino acid sequence of SEQ ID NO: 134. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 135. In some embodiments, the first binding domain comprises a light chain having an amino acid sequence of SEQ ID NO: 136. In some embodiments, the first binding domain comprises a heavy chain having an amino acid sequence of SEQ ID NO: 135, and a light chain having an amino acid sequence of SEQ ID NO: 136. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 133. In some embodiments, the first binding domain comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 134. In some embodiments, the first binding domain comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 133, and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 134. In someembodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the first binding domain comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 136. In some embodiments, the first binding domain comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 135, and a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 136.
[0152] In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Rabat numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the IMGT numbering system. In some embodiments, the VH CDR1, VH CDR2 and VH CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Exemplary numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Rabat numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Chothia numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the AbM numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Contact numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the IMGT numbering system. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3amino acid sequences of the first binding domain that binds TRGV9 are according to the Exemplary numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Rabat numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Chothia numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the AbM numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3,VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Contact numbering system. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the IMGT numbering system. In some embodiments, the VH CDR1,VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the first binding domain that binds TRGV9 are according to the Exemplary numbering system.
[0153] In some embodiments, the first binding domain binds a TRGV9 antigen.In some embodiments, the first binding domain binds a TRGV9 epitope. In some embodiments, the first binding domain specifically binds to TRGV9. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the first binding domain form a binding site for an antigen of the TRGV9.In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the first binding domain form a binding site for an epitope of the TRGV9. In some embodiments, the VH region and the VL region of the first binding domain form a binding site for an antigen of TRGV9. In some embodiments, the VH region and the VL region of the first binding domain form a binding site for an epitope of the TRGV9. In some embodiments, the heavy chain and the light chain of the first binding domain form a binding site for an antigen of TRGV9. In some embodiments, the heavy chain and the light chain of the second binding domain form a binding site for an epitope of TRGV9.
[0154] In some embodiments, the TRGV9 is present on the surface of a cell. In specific embodiment, the TRGV9 is present on the surface of a T cell. In a specific embodiment, the T cell is a gd T cell.
[0155] In some embodiments of the multispecific TRGV9 antibodies provided herein, the second target is CD123. In one embodiment of the multispecific TRGV9 antibodies provided herein, the second binding domain that binds CD123 comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 15. In one embodiment of the multispecific TRGV9 antibodies provided herein, the second binding domain that binds CD123 comprises a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 16. In one embodiment of the multispecific TRGV9 antibodies provided herein, the second binding domain that binds CD123 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 15; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 16. In one embodiment, the second binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:9, a VH CDR2 having an amino acid sequence of SEQ ID NO: 10, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 11, and (ii) a VL comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 12, a VL CDR2 having an amino acid sequence of SEQ ID NO: 13, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 14. In one embodiment, the second binding domain comprises: (i) a VH comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:556, a VH CDR2 having an amino acid sequence of SEQ ID NO:557, and a VH CDR3 having an amino acid sequence of SEQ ID...
Claims
What is Claimed is:
1. An antibody that binds T Cell Receptor Gamma Variable 9 (TRGV9) comprising:(1) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 104; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:105;(2) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 113; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 114;(3) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 123; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 124; or(4) (i) a VH comprising a VH CDR1 , a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 133; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:134.
2. The antibody of claim 1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Rabat numbering system.
3. The antibody of claim 1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Chothia numbering system.
4. The antibody of claim 1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the AbM numbering system.
5. The antibody of claim 1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Contact numbering system.
6. The antibody of claim 1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the IMGT numbering system.
7. The antibody of claim 1, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences are according to the Exemplary numbering system.
8. The antibody of any one of claims 1 to 7, wherein the antibody is a humanized antibody.
9. The antibody of any one of claims 1 to 8, wherein the antibody is an IgG antibody.
10. The antibody of claim 9, wherein the IgG antibody is an IgGl, IgG2, IgG3, or IgG4 antibody.
11. The antibody of any one of claims 1 to 10, wherein the antibody comprises a kappa light chain.
12. The antibody of any one of claims 1 to 10, wherein the antibody comprises a lambda light chain.
13. The antibody of any one of claims 1 to 12, wherein the antibody is a monoclonal antibody.
14. The antibody of any one of claims 1 to 13, wherein the antibody binds a TRGV9 antigen.
15. The antibody of any one of claims 1 to 13, wherein antibody binds a TRGV9 epitope.
16. The antibody of any one of claims 1 to 15, wherein the antibody specifically binds to TRGV9.
17. The antibody of any one of claims 1 to 16, wherein the VH CDR1, VH CDR2,VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form a binding site for an antigen of the TRGV9.
18. The antibody of any one of claims 1 to 16, wherein the VH CDR1, VH CDR2,VH CDR3, VL CDR1, VL CDR2 and VL CDR3 form a binding site for an epitope of the TRGV9.
19. The antibody of any one of claims 1 to 18, wherein the TRGV9 is present on the surface of a T cell.
20. The antibody of any one of claims 1 to 19, wherein the antibody is multivalent.
21. The antibody of claim 20, wherein the antibody is capable of binding at least three antigens.
22. The antibody of claim 20, wherein the antibody is capable of binding at least four antigens.
23. The antibody of claim 20, wherein the antibody is capable of binding at least five antigens.
24. The antibody of any one of claims 1 to 23, wherein the antibody is a multispecific antibody.
25. A multispecific TRGV9 antibody, comprising(a) a first binding domain that binds to TRGV9, wherein the first binding domain comprises a TRGV9 antibody of any one of claims 1 to 23, and(b) a second binding domain that binds to a second target that is not TRGV9.
26. The multispecific TRGV9 antibody of claim 25, wherein the antibody is a bispecific antibody.
27. The multispecific TRGV9 antibody of claim 25, wherein the antibody is a trispecific antibody.
28. The multispecific TRGV9 antibody of claim 25, wherein the antibody is a quadraspecific antibody.
29. The multispecific TRGV9 antibody of any one of claims 25 to 28, wherein the second binding domain binds an antigen of the second target.
30. The multispecific TRGV9 antibody of any one of claims 25 to 28, wherein second binding domain binds an epitope of the second target.
31. The multispecific TRGV9 antibody of any one of claims 25 to 30, wherein the second binding domain specifically binds to the second target.
32. The multispecific TRGV9 antibody of any one of claims 25 to 31, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the second binding domain form a binding site for an antigen of the second target.
33. The multispecific TRGV9 antibody of any one of claims 25 to 31, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of the second binding domain form a binding site for an epitope of the second target.
34. The multispecific TRGV9 antibody of any one of claims 25 to 33, wherein the second target is present on the surface of a target cell.
35. The multispecific TRGV9 antibody of any one of claims 25 to 34, wherein the second binding domain that binds the second target is multivalent.
36. The multispecific TRGV9 antibody of claim 35, wherein the second binding domain is capable of binding at least three antigens.
37. The multispecific TRGV9 antibody of claim 35, wherein the second binding domain is capable of binding at least four antigens.
38. The multispecific TRGV9 antibody of claim 35, wherein the second binding domain is capable of binding at least five antigens.
39. The multispecific TRGV9 antibody of any one of claim 25 to 38, wherein the second target is CD 123.
40. The multispecific TRGV9 antibody of claim 39, wherein the second binding arm that binds CD 123 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 15; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 16.
41. A multispecific TRGV9 antibody, comprising(a) a first binding domain that binds to TRGV9, wherein the first binding domain comprises:(1) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:7; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8;(2) (i) a VH CDR1 , a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:34; and (ii) a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8;(3) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:35; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8;(4) (i) a VH comprising a VH CDR1 , a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and aVH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:36; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:8;(5) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:66;(6) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:67; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:68; or(7) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:95; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:96; and(b) a second binding domain that binds to a second target that is CD33,TRBC1, BCMA or PSMA.
42. The multispecific TRGV9 antibody of any one of claims 25 to 35 or 41, wherein the second target is CD33.
43. The multispecific TRGV9 antibody of claim 42, wherein the second binding arm that binds CD33 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:43; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:44.
44. The multispecific TRGV9 antibody of any one of claims 25 to 38 or 41, wherein the second target is TRBC1.
45. The multispecific TRGV9 antibody of claim 44, wherein the second binding arm that binds TRBC1 comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:55; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:56.
46. The multispecific TRGV9 antibody of any one of claims 25 to 38 or 41, wherein the second target is BCMA.
47. The multispecific TRGV9 antibody of claim 46, wherein the second binding arm that binds BCMA comprises: (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO: 143; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO: 144.
48. The multispecific TRGV9 antibody of any one of claims 25 to 38 or 41, wherein the second target is PSMA.
49. The multispecific TRGV9 antibody of claim 48, wherein the second binding arm that binds PSMA comprises: (i) a VH comprising a VH CDR1, a VH CDR2, anda VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:775; and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:776.
50. The multispecific TRGV9 antibody of any one of claims 40, 43, 45, 47 or 49, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the Rabat numbering system.
51. The multispecific TRGV9 antibody of any one of claims 40, 43, 45, 47 or 49, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the Chothia numbering system.
52. The multispecific TRGV9 antibody of any one of claims 40, 43, 45, 47 or 49, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the AbM numbering system.
53. The multispecific TRGV9 antibody of any one of claims 40, 43, 45, 47 or 49, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the Contact numbering system.
54. The multispecific TRGV9 antibody of any one of claims 40, 43, 45, 47 or 49, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the IMGT numbering system.
55. The multispecific TRGV9 antibody of any one of claims 40, 43, 45, 47 or 49, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the Exemplary numbering system.
56. A multispecific TRGV9 antibody, comprising a first means capable of binding TRGV9 on the surface of the T cell; and a second means capable of binding a second target that is not TRGV9.
57. The multispecific TRGV9 antibody of claim 56, wherein the second target is present on the surface of a target cell.
58. A nucleic acid encoding the antibody of any one of claims 1 to 57.
59. A vector comprising the nucleic acid of claim 58.
60. A host cell comprising the vector of claim 59.
61. A kit comprising the vector of claim 59 and packaging for the same.
62. A kit comprising the antibody of any one of claims 1 to 57 and packaging for the same.
63. A pharmaceutical composition comprising the antibody of any one of claims 1 to 57, and a pharmaceutically acceptable carrier.
64. A method of producing the pharmaceutical composition of claim 63, comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.
65. A method of activating a T cell expressing TRGV9, comprising contacting the T cell with the antibody of any one of claims 1 to 57.
66. The method of claim 65, wherein the contacting results in an increase in CD69, CD25, and / or Granzyme B expression, as compared to a control T cell expressing TRGV9.
67. A process for making an antibody that binds to more than one target molecule, the process comprising: a step for performing a function of obtaining a first binding domain that binds to TRGV9 present on a T cell; a step for performing a function of obtaining a second binding domain that binds to a second target on the surface of a target cell; and a step for performing a function of providing an antibody that binds to TRGV9 present on a T cell and a second target on the surface of a target cell.
68. The process of claim 67, wherein the step for performing a function of obtaining a second binding domain that binds to a second target on the surface of a target cell is repeated n times, and further comprising n steps for performing a function ofproviding a first binding domain that binds to TRGV9 present on a T cell and n number of target molecules, wherein n is at least 2.
69. A method of directing a T cell expressing TRGV9 to a target cell, comprising contacting the multispecific TRGV9 antibody of any one of claims 25 to 57 with the target cell, wherein the second target is present on the surface of the target cell, and wherein the contacting directs the T cell to the target cell.
70. A method of inhibiting the growth or proliferation of a target cell, comprising contacting the multispecific TRGV9 antibody of any one of claims 25 to 57 with the target cell having the second target present on the surface of the target cell, wherein the contacting is in the presence of a T cell expressing the TRGV9, and wherein the contacting results in the inhibition of the growth or proliferation of the target cell.
71. A method of eliminating a target cell in a subject, comprising contacting the multispecific TRGV9 antibody of any one of claims 25 to 57 with the target cell having the second target present on the surface of the target cell, wherein the contacting is in the presence of a T cell expressing the TRGV9, and wherein the contacting results in the elimination of the target cell.
72. A method of treating a disease in a subject, comprising administering an effective amount of the multispecific TRGV9 antibody of any one of claims 25 to 57 to the subject, wherein the disease is caused all or in part by a target cell having the second target present on the surface of the target cell.
73. The method of claim 71 or 72, wherein the subject is a human.
74. The method of any one of claims 71 to 73, wherein the subject is a subject in need thereof.
75. The multispecific TRGV9 antibody of any one of claims 26 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a cancer cell.
76. The multispecific TRGV9 antibody or method of claim 75, wherein(i) the cancer cell is a cell of an adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer,gestational trophoblastic, head and neck cancer, Hodgkin lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumor, non- Hodgkin lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma spinal cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer endometrial cancer, vaginal cancer, or vulvar cancer;(ii) second target is angiopoietin, BCMA, CD 19, CD20, CD22, CD25 (IL2- R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL / Notch, EGFR, EpCAM, FGF, FGF-R, GD2, HER2, Mesothelin, Nectin-4, PAP, PDGFRa, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAPl, TARP, TROP2, VEGF, or VEGF-R; and / or(iii) the second target is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcium-activated chloride channel 2, cyclin-Bl, 9D7, EpCAM, EphA3, Her2 / neu, tel om erase, mesothelin, SAP-1, surviving, a BAGE family antigen, CAGE family antigen, GAGE family antigen, MAGE family antigen, SAGE family antigen, XAGE family antigen, NY- ESO-l / LAGE-1, PRAME, SSX-2, Melan-A, MART-1, GplOO, pmell7, tyrosinase, TRP-1, TRP-2, P. polypeptide, MC1R, prostate-specific antigen, b-catenin, orBRCAl.
77. The multispecific TRGV9 antibody or method of claim 75, wherein the second target is CD 123.
78. The multispecific TRGV9 antibody or method of claim 75, wherein the second target is CD33.
79. The multispecific TRGV9 antibody or method of claim 75, wherein the second target is BCMA.
80. The multispecific TRGV9 antibody or method of claim 75, wherein the second target is PSMA.
81. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a T cell.
82. The multispecific TRGV9 antibody or method of claim 81, wherein the second target is CDR3, CD16, CD17, CD18, CD20, CD21, CD23, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32b, CD35, CD37, CD38, CD39, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD62L, CD63, CD68, CD69, CD70, CD71, CD73, CD74, CD75S, CD80, CD81, CD82, CD84, CD85A, CD85J, CD86,CD87, CD92, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD 100,CD101, CD 102, CD103, CD107a, CD107b, CD108, CD109, CD119, CD120a, CD 120b, CD121a, CD121b, CD122, CD124, CD126, CD127, CD128, CD129, CD130, CD132, CD134, CD137, CD146, CD147, CD148, CD150, CD152, CD153, CD 154, CD156b, CD158a, CD158M, CD158b2, CD158el / e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, CD160, CD161, CD162, CD 164, CD172g, CD178, CD181, CD182, CD183, CD184, CD185, CD186, CD191, CD 192, CD193, CD194, CD195, CD196, CD197, CDwl98, CDwl99, CD205, CD210a, CDw210b, CD212, CD215, CD217, CD218a, CD218b, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD229, CD230, CD231, CD244, CD245, CD246, CD247, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267, CD268, CD270, CD272, CD273, CD274, CD275, CD277, CD278, CD279, CD283, CD288, CD289, CD290, CD294, CD295, CD296, CD298, CD300a, CD300c, CD300e, CD305, CD306, CD307c, CD314, CD316, CD317, CD319, CD321, CD328, CD351, CD352, CD352, CD354, CD355, CD357, CD358, CD359, CD360, CD361, CD362, or CD363.
83. The multispecific TRGV9 antibody or method of claim 81, wherein the second target is TRBC1.
84. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a B cell.
85. The multispecific TRGV9 antibody or method of claim 84, wherein the second target is CDla, CDlb, CDlc, CDld, CD2, CD5, CD6, CD9, CDl la, CDl lb,CDl lc, CD 17, CD 18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD50, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85E, CD85I, CD85J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, CD120a, CD 120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166,CD 167a, CD 170, CD171, CD175, CD175s, CD180, CD184, CD185, CD192,CD 196, CD 197, CD200, CD205, CD201a, CDw210b, CD212, CD213al, CD213a2, CD 215, CD217, CD218a, CD218b, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267-270, CD272, CD274, CD275, CD277, CD279, CD283, CD289, CD290, CD295, CD298, CD300, CD300c, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD314, CD215, CD316, CD317, CD319, CD321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD360, CD361, CD362 or CD363.
86. The multispecific TRGV9 antibody of claim 84, wherein the second target is BCMA.
87. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a dendritic cell.
88. The multispecific TRGV9 antibody or method of claim 87, wherein the second target is CDla, CDlb, CDlc, CDld, CDle, CDl lb, CDl lc, CD16, CD17, CD18, CD 19, CD21, CD23, CD29, CD33, CD35, CD36, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD48, CD49d, CD49e, CD58, CD64a, CD68, CD73, CD74, CD80, CD81, CD83, CD84, CD85A, CD85D, CD85E, CD85G, CD85J, CD86, CD88, CD97, CD101, CD116, CD120a, CD120b,CD123, CD139, CD148, CD150, CD156b, CD157, CD167, CD168, CD169,CD 170, CD171, CD172a, CD172b, CD180, CD184, CD185, CD193, CD196,CD 197, CD200, CD205, CD206, CD207, CD208, CD209, CDw210b, CD213al, CD217, CD218a, CD218b, CD220, CD221, CD222, CD227, CD229, CD230, CD232, CD244, CD252, CD256, CD257, CD258, CD265, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD283, CD286, CD288, CD289, CD290, CD295, CD298, CD300a, CD300c, CD300e, CD301, CD302, CD303, CD304, CD305, CD312, CD317, CD319, CD320, CD328, CD352, CD354, CD357, or CD361.
89. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a NK cell.
90. The multispecific TRGV9 antibody or method of claim 89, wherein the second target is CD2, CD7, CD8a, CD10, CDl la, CDl lb, CDl lc, CDwl2, CD16,CD 18, CD25, CD26, CD27, CD29, CD30, CD31, CD32c, CD38, CD39, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49d, CD49e, CD50, CD52, CD53, CD55, CD56, CD7, CD58, CD59, CD62L, CD63, CD69, CD81, CD82, CD84, CD85C, CD85E, CD85J, CD87, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD119,CD 120a, CD 120b, CD122, CD130, CD132, CD147, CD148, CD158a, CD158M, CD158b2, CD158d, CD158el / e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD 158k, CD 159a, CD159c, CD160, CD161, CD172g, CD178, CD183, CD185, CDw210b, CD212, CD217, CD218a, CD218b, CD220, CD221, CD222, CD223, CD225, CD226, CD229, CD230, CD232, CD244, CD247, CD257, CD261, CD262, CD263, CD264, CD270, CD277, CD280, CD295, CD298, CD305, CD314, CD316, CD317, CD319, CD321, CD328, CD329, CD335, CD336, CD337, CD352, CD354, CD355, CD357, CD360, CD361, or CD363.
91. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a stem cell or stem cell precursor.
92. The multispecific TRGV9 antibody or method of claim 91, wherein the second target is CD8a, CDwl2, CD13, CD15, CD19, CD21, CD22, CD29, CD30, CD33,CD34, CD36, CD38, CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD48, CD49b, CD49d, CD49e, CD49f, CD50, CD53, CD55, CD64a, CD68, CD71, CD72, CD73, CD81, CD82, CD85A, CD85K, CD90, CD99, CD104, CD105, CD109, CD110, CD111,CD112, CD114, CD115, CD117, CD123, CD124, CD126, CD127, CD130, CD131, CD133, CD135, CD138, CD151, CD157, CD162, CD164, CD168,CD 172a, CD173, CD174, CD175, CD175s, CD176, CD183, CD191, CD200, CD201, CD205, CD217, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD235a, CD235b, CD236, CD236R, CD238, CD240, CD242, CD243, CD277, CD292, CDw293, CD295, CD298, CD309, CD318, CD324, CD325, CD338, CD344, CD349, or CD350.
93. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a monocyte or macrophage.
94. The multispecific TRGV9 antibody or method of claim 93, wherein the second target is CDla, CDlb, CDlc, CD4, CD9, CDl la, CDl lb, CDl lc, CDl ld, CDwl2, CD13, CD 14, CD15, CD16, CD17, CD18, CD23, CD25, CD26, CD29, CD30, CD31, CD32a, CD32b, CD32c, CD33, CD35, CD36, CD37, CD38, CD39, CD40, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD58, CD59, CD60a, CD61, CD63, CD64a, CD65, CD66, CD68, CD69, CD72, CD74, CD75, CD75S, CD80, CD81, CD82, CD84, CD85A, CD85C, CD85D, CD85E, CD85F, CD85G, CD85I, CD85J, CD85K, CD86, CD87, CD88, CD89, CD91, CD92, CD93, CD95, CD97, CD98, CD99, CD99R, CD 100, CD101, CD 102, CD105, CD111, CD112, CD114, CD115, CD116, CD119, CD 120a, CD120b, CD121b, CD122, CD124, CD127, CD130, CD131, CD 132, CD136, CD137, CD139, CD141, CD142, CD143, CD147, CD148, CD153, CD155, CD156a, CD156b, CD156c, CD157, CD162, CD163, CD164, CD165, CD 166, CD168, CD169, CD170, CD171, CD172a, CD172b, CD180, CD181, CD 182, CD184, CD185, CD191, CD192, CD194, CD195, CDwl98, CD24, CD205, CD206, CD209, CD210a, CDw210b, CD213al, CD213a2,, , , , , , , ,95. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a granulocyte.
96. The multispecific TRGV9 antibody or method of claim 95, wherein the second target is CD1 la, CDllb, CDllc, CDwl2, CD13, CD14, CD15, CD16, CD16b, C C C C CC CCC C C C CD314, CD321, CD328, CD329, CD352, CD354, CD360, or CD362.
97. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is a platelet.
98. The multispecific TRGV9 antibody or method of claim 97, wherein the second target is, , , , , , , , , ,99. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is an erythrocyte.
100. The multispecific TRGV9 antibody or method of claim 99, wherein the second target isC C or C101. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is is an endothelial cell.
102. The multispecific TRGV9 antibody or method of claim 101, wherein the second target is,103. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is present on the surface of a target cell, and wherein the target cell is an epithelial cell.
104. The multispecific TRGV9 antibody or method of claim 103, wherein the second target is CDld, CD9, CD13, CD18, CD21, CD23, CD24, CD26, CD29, CD39, CD40, CD44, CD46, CD47, CD49b, CD49c, CD49e, CD49f, CD52, CD55,CD58, CD66a, CD66c, CD66e, CD66f, CD73, CD74, CD75S, CD77, CD81, CD82, CD88. 91, CD92, CD98, CD99, CD104, CD110, CD111, CD112, CD113, CD114, CD118, CD120a, CD120b, CD124, CD129, CD133, CD136, CD137, CD138, CD141, CD142, CD143, CDwl45, CD151, CD164, CD165, CD166,CD 167a, CD171, CD174, CD175, CD175S, CD176, CD178, CD193, CD206, CD213a2, CD217, CD220, CD221, CD222, CD224, CD227, CD230, CD234, CD239, CD249, CD286, CD295, CD296, CD321, CD324, CD326, CD331, CD332, CD333, CD334, CD339, CD340, CD344, or CD350.
105. The multispecific TRGV9 antibody of any one of claims 25 to 57 or the method of any one of claims 69 to 74, wherein the second target is a pathogen, optionally wherein the target cell is a cell having a pathogen antigen on the surface of the target cell.
106. The multispecific TRGV9 antibody or method of claim 105, wherein the pathogen is a virus.
107. The multispecific TRGV9 antibody or method of claim 106, wherein the virus is a virus of the adenoviridae, arenaviridae, astroviridae, bunyaviridae, caliciviridae, coronaviridae, filoviridae, flaviviridae, hepadnaviridae, hepeviridae, orthomyxoviridae, papillomaviridae, paramyxoviridae, parvoviridae, picornaviridae, polyomaviridae, poxviridae, reoviridae, retroviridae, rhabdoviridae, or togaviridae family.
108. The multispecific TRGV9 antibody or method of claim 106, wherein the virus is an adenovirus, coronavirus, coxsackievirus, Epstein-Barr virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus type 2, cytomegalovirus, human herpes virus type 8, human immunodeficiency virus, influenza virus, measles virus, mumps virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, or varicella- zoster virus.
109. The multispecific TRGV9 antibody or method of claim 105, wherein the pathogen is a bacteria.
110. The multispecific TRGV9 antibody or method of claim 109, wherein the bacteria is a bacteria of a bacillus, bartonella, bordetella, borrelia, brucella, Campylobacter, chlamydia, chlamydophila, Clostridium, corynebacterium, enterococcus, escherichia, francisella, haemophilus, helicobacter, legionella, leptospira, listeria, mycobacterium, mycoplasma, neisseria, pseudomonas, rickettsia, salmonella, shigella, staphylococcus, streptococcus, treponema, ureaplasma, vibrio or yersinia genus.
111. The multispecific TRGV9 antibody or method of claim 105, wherein the pathogen is a parasite.
112. The multispecific TRGV9 antibody or method of claim 111, wherein the parasite is a protozoa, helminth, or ectoparasite.
113. The multispecific TRGV9 antibody or method of claim 112, wherein(i) the protozoa is an entamoeba, giardia, leishmania, balantidium, plasmodium, or Cryptosporidium;(ii) the helminth is a trematode, cestode, acanthocephalan, or round worm; or(iii) the ectoparasite is a arthropod.
114. The multispecific TRGV9 antibody or method of claim 105, wherein the pathogen causes an infectious disease selected from the group consisting of an Acute Flaccid Myelitis (AFM), Anaplasmosis, Anthrax, Babesiosis, Botulism, Brucellosis, Campylobacteriosis, Carbapenem-resistant Infection, Chancroid, Chikungunya Virus Infection, Chlamydia, Ciguatera, Difficile Infection, Perfringens, Coccidioidomycosis fungal infection, coronavirus infection, Covid- 19 (SARS-CoV-2), Creutzfeldt-Jacob Disease / transmissible spongiform encephalopathy, Cryptosporidiosis (Crypto), Cyclosporiasis, Dengue 1,2,3 or 4, Diphtheria, E. coli infection / Shiga toxin-producing (STEC), Eastern Equine Encephalitis, Hemorrhagic Fever (Ebola), Ehrlichiosis, Encephalitis, Arboviral or parainfectious, Non-Polio Enterovirus, D68 Enteroviru(EV-D68), Giardiasis, Glanders, Gonococcal Infection, Granuloma inguinale, Haemophilus Influenza disease Type B (Hib or H-flu), Hantavirus Pulmonary Syndrome (HPS),Hemolytic Uremic Syndrome (HUS), Hepatitis A (Hep A), Hepatitis B (Hep B), Hepatitis C (Hep C), Hepatitis D (Hep D), Hepatitis E (Hep E), Herpes, Herpes Zoster (Shingles), Histoplasmosis infection, Human Immunodeficiency Virus / AIDS (HIV / AIDS), Human Papillomavirus (HPV), Influenza (Flu), Legionellosis (Legionnaires Disease), Leprosy (Hansens Disease), Leptospirosis, Listeriosis (Listeria), Lyme Disease, Lymphogranuloma venereum infection (LGV), Malaria, Measles, Melioidosis, Meningitis (Viral), Meningococcal Disease (Meningitis (Bacterial)), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Mumps, Norovirus, Pediculosis, Pelvic Inflammatory Disease (PID), Pertussis (Whooping Cough), Plague (Bubonic, Septicemic, Pneumonic), Pneumococcal Disease (Pneumonia), Poliomyelitis (Polio), Powassan, Psittacosis, Pthiriasis, Pustular Rash diseases (Small pox, monkeypox, cowpox), Q-Fever, Rabies, Rickettsiosis (Rocky Mountain Spotted Fever), Rubella (German Measles), Salmonellosis gastroenteritis (Salmonella), Scabies, Scombroid, Sepsis, Severe Acute Respiratory Syndrome (SARS), Shigellosis gastroenteritis (Shigella), Smallpox, Staphyloccal Infection Methicillin-resistant (MRSA), Staphylococcal Food Poisoning Enterotoxin B Poisoning (Staph Food Poisoning), Saphylococcal Infection Vancomycin Intermediate (VISA), Staphylococcal Infection Vancomycin Resistant (VRSA), Streptococcal Disease Group A (invasive) (Strep A (invasive), Streptococcal Disease, Group B (Strep-B), Streptococcal Toxic-Shock Syndrome STSS Toxic Shock, Syphilis (primary, secondary, early latent, late latent, congenital), Tetanus Infection, Trichomoniasis, Trichonosis Infection, Tuberculosis (TB), Tuberculosis Latent (LTBI), Tularemia, Typhoid Fever Group D, Vaginosis, Varicella (Chickenpox), Vibrio cholerae (Cholera), Vibriosis (Vibrio), Ebola Virus Hemorrhagic Fever, Lasa Virus Hemorrhagic Fever, Marburg Virus Hemorrhagic Fever, West Nile Virus, Yellow Fever, Yersenia, and Zika Virus Infection.
